<div class="chapter"><div class="chapter"><h2 class="title">CHAPTER 18. <a name="page330"></a><span class="pageBreak"></span><span class="pageNumbers"><span class="bottomPage">330</span></span>Diseases of the Retina</h2><div class="section" id="ch18lev1sec1"><h1 class="title">SYMPTOMS AND SIGNS</h1>
<ul style="list-style-type: bullet">
<li><p class=""><span class="italic">Dimi nution of vision without pain.</span></p></li>
<li><p class=""><span class="italic">Night blindness:</span> In diseases those predominantly affect the function of rods.</p></li>
<li><p class=""><span class="italic">Peripheral constriction of the visual field</span> or <span class="italic">scotoma</span> may be present corresponding with the areas, especially affected.</p></li>
<li><p class=""><span class="italic">Metamorphopsia (distorted images) micropsia</span> <span class="italic">(small images), or macropsia (large images):</span> It may be present in macular lesions.</p></li>
<li><p class=""><span class="italic">Photopsia</span> (sparks or lightning flashes) occurs due to traction upon the retina.</p></li>
<li><p class=""><span class="italic">Frequently</span>, the patient is unaware of symptoms, and the abnormality is only detected during routine ophthalmoscopic examination.</p></li>
</ul>
</div><div class="section" id="ch18lev1sec2"><h1 class="title">OPHTHALMOSCOPIC FINDINGS</h1>
<ul style="list-style-type: bullet">
<li><p class=""><span class="italic">Disturbances of the blood vessels:</span> Examples are vascular pulsation, venous dilatation, arteriovenous ratio and arteriovenous crossing changes, any abnormal vascular reflex, neovascularization of the disc (NVD, and/or elsewhere—NVE), hemorrhages (superficial or deep), and microaneurysms.</p></li>
<li><p class=""><span class="italic">Opacities in the sensory retina</span>: Examples are soft exudates (cotton-wool patches), hard exudates, hemorrhages, edema residues and glial tissue proliferation.</p></li>
<li><p class=""><span class="italic">Disturbances in the attachment of the sensory retina:</span> Examples are rhegmatogenous retinal detachment (with a retinal break) and non-rhegmatogenous retinal detachment (without a retinal break).</p></li>
<li><p class=""><span class="italic">Disturbances in the retinal pigment epithelium (RPE):</span> Examples are decreased or increased pigmentation (dark areas).</p></li>
<li><p class=""><span class="italic">Abnormalities of Bruch's membrane:</span> Examples are breaks in Bruch's membrane with replacement by fibrous tissue, as in angioid streak and drusen. Both of these conditions favor the formation of subretinal neovascular membrane.</p></li>
<li><p class=""><span class="italic">Peripheral retinal lesions</span> are best seen with an indirect ophthalmoscope, or Goldmann's three mirror gonioscope by a slit-lamp.</p></li>
<li><p class="">Appearance of the normal fundus as seen with the direct ophthalmoscope <bold>(<a href="#ch18fig1" class="ulink-inter">Fig. 18.1</a>)</bold>.</p></li>
</ul>
<div class="figure" id="ch18fig1" data-label="Fig. 18.1"><div class="title"><span class="item-label">Fig. 18.1</span> Normal fundus.</div><img alt="Fig. 18.1" src="/MediumImage/330-1.jpg"><div class="additional-markup"></div></div>
<p class=""><a name="page331"></a><span class="pageBreak"></span><span class="pageNumbers"><span class="bottomPage">331</span></span></p>
</div><div class="section" id="ch18lev1sec3"><h1 class="title">EXAMINATION OF THE FUNDUS</h1>
<ul style="list-style-type: bullet">
<li><p class=""><span class="italic">Examination with a retinoscopic plane mirror from 1 m distance:</span> To know the fundal glow and refractive status of the patient's eye.</p></li>
<li><p class=""><span class="italic">Examination by an ophthalmoscope or a plane mirror at 22 cm distance (distant direct ophthalmoscopy):</span> Opacities in the anterior segment can be readily visualized.</p></li>
<li><p class=""><span class="italic">Direct ophthalmoscopy:</span> The details of central retina are examined under higher magnification (15 times). The image is direct and erect, seen uniocularly.</p></li>
<li><p class=""><span class="italic">Indirect ophthalmoscopy:</span> With this up to the peripheral portion of retina is visualized. Magnification is 3–5 times. But the image is real and inverted. Depth of lesion is better judged as it is binocular.</p></li>
<li><p class=""><span class="italic">Slit-lamp</span> and special lenses:
<ul style="list-style-type: square">
<li><p class="">Hruby lens</p></li>
<li><p class="">Fundus contact lens</p></li>
<li><p class="">Goldmann's three-mirror contact lens</p></li>
<li><p class="">+90D or +78D lens</p></li>
</ul></p></li>
</ul>
<p class="noindent">Fundus examination includes:</p>
<ul style="list-style-type: bullet">
<li><p class=""><span class="italic">Fundal glow:</span> Good, poor or absent.</p></li>
<li><p class=""><span class="italic">Optic disc:</span> Margin, color, size, shape, cup-to-disc ratio, neural rim, venous pulsation, any abnormal vessels or lesions.</p></li>
<li><p class=""><span class="italic">Retinal blood vessels:</span> Vascular reflexes, A-V ratio, A-V crossing, any abnormal or new vessels.</p></li>
<li><p class=""><span class="italic">Macula and foveal reflex:</span> Any abnormality, i.e., cyst, hole, hemorrhages, edema, scar, etc.</p></li>
<li><p class=""><span class="italic">General fundus:</span> Any abnormality, e.g., exudates, hemorrhage, pigmentation, scar, new vessels, detached area, coloboma, folds, etc.</p></li>
<li><p class=""><span class="italic">Peripheral fundus:</span> It is (best seen by an indirect ophthalmoscope) for retinal break (hole/tear), degenerated area, pigmentation, exudation, etc.</p></li>
<li><p class=""><span class="italic">Choroidal blood vessels:</span> Normally not visible, but in case of sclerosis they are visible as ribbons.</p></li>
</ul>
</div><div class="section" id="ch18lev1sec4"><h1 class="title">METHODS OF OPHTHALMOSCOPY</h1>
<p class="noindent">There are two forms of ophthalmoscopy—(1) <span class="italic">Direct</span> and (2) <span class="italic">indirect</span>.</p>
<div class="section" id="ch18lev2sec1"><h2 class="title">Direct Ophthalmoscopy</h2>
<p class="noindent">The hand-held direct ophthalmoscope is designed to provide a direct magnified (×15) view of the fundus. The source of illumination is projected by means of a mirror or prism coinciding with the observer's line of vision through the aperture.</p>
<ul style="list-style-type: bullet">
<li><p class="">The ophthalmoscope is held close to the observer's eye and approximately 15 cm from the patient's eye.</p></li>
<li><p class="">It is held in the right hand to examine patient's right eye and in the left hand to examine patient's left eye.</p></li>
<li><p class="">The observer uses his/her right eye to examine patient's right eye and left eye for patient's left eye.</p></li>
<li><p class="">The patient should fix on a distant target with the eye as steady as possible.</p></li>
<li><p class="">The observer have to adjust ophthalmoscope power setting to accommodate for the patient's refractive error and/or his/her own.</p></li>
<li><p class="">If both patient and observer are emmetropic, the lens is set at zero. A red reflex will be seen and is considered normal.</p></li>
<li><p class="">Moving the ophthalmoscope as close to the patient's eye as possible and using the plus or minus lens, the observer will be able to see central retina in detail up to the equator.</p></li>
<li><p class="">Lens setting at more plus power will focus the ophthalmoscope in the vitreous or more anterior.</p></li>
</ul>
</div>
<div class="section" id="ch18lev2sec2"><h2 class="title">Indirect Ophthalmoscopy</h2>
<p class="noindent">This technique is generally used by retina specialist and involves the use of a head mounted, prism directed light source coupled with use of a high condensing lens (+14, +20 or +30D) to see the retinal image. A +20D condensing lens is more commonly used.<a name="page332"></a><span class="pageBreak"></span><span class="pageNumbers"><span class="bottomPage">332</span></span></p>
<p class="indent">The retinal image formed by indirect ophthalmoscopy is inverted, real and capable of being seen at the focal plane of the lens.</p>
<p class="indent">The image is brilliantly illuminated, binocular stereoscopic one that covers approximately 10 times of the area compare to direct ophthalmoscope. The image is, however, smaller (×3 times). It is essential to see retinal periphery to locate different types of lesions. Because of its stronger illumination, it allows light to pass through moderate opacities in the media which are obstructive to direct ophthalmoscope.</p>
</div>
</div><div class="section" id="ch18lev1sec5"><h1 class="title">CONGENITAL AND DEVELOPMENTAL ABNORMALITIES</h1>
<div class="section" id="ch18lev2sec3"><h2 class="title">Myelinated Optic Nerve Fibers (<a href="#ch18fig2" class="ulink-inter">Fig. 18.2</a>)</h2>
<ul style="list-style-type: bullet">
<li><p class="">The myelin sheaths of the optic nerve fibers cease normally at the lamina cribrosa.</p></li>
<li><p class="">Sometimes, this myelination extends a short distance over the retinal surface adjacent to the disc.</p></li>
<li><p class=""><span class="italic">Ophthalmoscopically</span>, they appear as white patches with radial striations at peripheral edges. Usually, the patches are continuous with the disc, but occasionally they are isolated. The retinal vessels are covered at places by the opaque fibers.</p></li>
<li><p class="">When present, the blind spot is often enlarged, or a scotoma corresponds with the position of the patch.</p></li>
<li><p class="">They must be differentiated from soft exudates, as seen in hypertensive retinopathy, and from papilledema.</p></li>
<li><p class="">The myelin sheaths disappear in optic atrophy (due to any cause) and no trace of abnormality remains.</p></li>
<li><p class="">No treatment is required.</p></li>
</ul>
<div class="figure" id="ch18fig2" data-label="Fig. 18.2"><div class="title"><span class="item-label">Fig. 18.2</span> Myelinated optic nerve.</div><img alt="Fig. 18.2" src="/MediumImage/332-1.jpg"><div class="additional-markup"></div></div>
</div>
<div class="section" id="ch18lev2sec4"><h2 class="title">Phakomatosis</h2>
<p class="noindent">This is a group of conditions (hamartomas) in which there are congenital, disseminated, usually benign tumors of the blood vessels or neural tissues. They are often ocular, cutaneous, and intracranial in location.</p>
<p class="noindent">The variety of conditions are:</p>
<ul style="list-style-type: bullet">
<li><p class="">Neurofibromatosis <span class="italic">(von Recklinghausen)</span></p></li>
<li><p class="">Tuberous sclerosis <span class="italic">(Bourneville)</span></p></li>
<li><p class="">Angiomatosis retinae with cerebellar hemangioblastoma <span class="italic">(von Hippel-Lindau)</span></p></li>
<li><p class="">Encephalotrigeminal angiomatosis <span class="italic">(Sturge-Weber)</span></p></li>
<li><p class="">Ataxia telangiectasia <span class="italic">(Louis-Bar)</span></p></li>
<li><p class="">Encephalo-retino-facial angiomatosis (<span class="italic">Wyburn Mason).</span></p></li>
</ul>
<div class="section" id="ch18lev3sec1"><h3 class="title">Neurofibromatosis (von Recklinghausen's Disease)</h3>
<ul style="list-style-type: bullet">
<li><p class="">It is the most common type, with typical subcutaneous nodules and <span class="italic">cafe-au-lait spots</span>.</p>
<p class=""><span class="italic">Ocular manifestations:</span> Plexiform tumors of lids with ptosis, thickened corneal nerves, <span class="italic">Leish's nodules</span> <bold>(<a href="#ch18fig3" class="ulink-inter">Fig. 18.3</a>)</bold> on the iris, pulsating proptosis (due to transmitted cerebral pulsations through the defects in the orbital walls), glioma of the optic nerve, and congenital glaucoma.</p></li>
<li><p class="">Operative measures are seldom satisfactory.</p></li>
</ul>
</div>
<div class="section" id="ch18lev3sec2"><h3 class="title">Tuberous Sclerosis (<a href="#ch18fig4" class="ulink-inter">Figs. 18.4A and B</a>) (Bourneville's Disease)</h3>
<ul style="list-style-type: bullet">
<li><p class="">The diagnostic triad are epilepsy, mental retardation and adenoma sebaceum (angiofibroma).<a name="page333"></a><span class="pageBreak"></span><span class="pageNumbers"><span class="bottomPage">333</span></span></p>
<p class=""><div class="figure" id="ch18fig3" data-label="Fig. 18.3"><div class="title"><span class="item-label">Fig. 18.3</span> Leish's nodules in neurofibromatosis.</div><img alt="Fig. 18.3" src="/MediumImage/333-1.jpg"><div class="additional-markup"></div></div></p>
<p class="">It is also called <span class="italic">epiloia</span>-<span class="italic">epi</span> (epilepsy)-<span class="italic">loi</span> (low IQ)-<span class="italic">a</span> (adenoma sebaceum).</p></li>
<li><p class=""><span class="italic">Ocular lesion:</span> Multiple nodular tumors are seen springing from the optic disc, like white mulberries (astrocytoma).</p></li>
<li><p class="">Glial hamartomas of the cerebrum result in seizures, and cochlear (acoustic) nerve is most frequently involved.</p></li>
</ul>
</div>
<div class="section" id="ch18lev3sec3"><h3 class="title">Angiomatosis Retinae (<a href="#ch18fig5" class="ulink-inter">Fig. 18.5) (von Hippel-Lindau's Disease</a>)</h3>
<ul style="list-style-type: bullet">
<li><p class="">It is classically seen in the retina and in the cerebellum.</p></li>
<li><p class=""><span class="italic">Ophthalmoscopically:</span> A reddish, slightly elevated tumor is seen in the retina, which is nourished by dilated large retinal artery and vein. The retina becomes spattered with hemorrhages and exudates, ultimately leading to vitreous hemorrhage, retinal detachment and secondary glaucoma.</p></li>
<li><p class="">When localized, the secondary complications can be prevented by photocoagulation.</p></li>
</ul>
</div>
<div class="section" id="ch18lev3sec4"><h3 class="title">Encephalotrigeminal Angiomatosis (Sturge-Weber's Syndrome) (<a href="#ch18fig6" class="ulink-inter">Fig. 18.6</a>)</h3>
<ul style="list-style-type: bullet">
<li><p class="">There is <span class="italic">nevus flammeus</span> (port-wine stain) along the distribution of the trigeminal nerve of the affected side.</p></li>
<li><p class="">There is an associated <span class="italic">choroidal hemangioma</span> which may result in a congenital or childhood glaucoma.</p></li>
<li><p class="">Focal seizures and mental retardation are also common.</p></li>
<li><p class="">A characteristic X-ray finding is cortical calcifications which appear as double densities <span class="italic">(train-tract</span> or <span class="italic">rail-road</span> sign).</p></li>
</ul>
</div>
</div>
<div class="section" id="ch18lev2sec5"><h2 class="title">Coats’ Disease (<a href="#ch18fig7" class="ulink-inter">Figs. 18.7A and B</a>)</h2>
<ul style="list-style-type: bullet">
<li><p class="">This is a chronic, progressive, vascular abnormality in which telangiectatic retinal vessels leak fluid, which results in an exudative bullous retinal detachment.</p></li>
<li><p class="">It usually affects boys between 18 months and 18 years of age.</p></li>
<li><p class="">It is usually unilateral, but both eyes may also be affected.</p></li>
</ul>
<div class="figure" id="ch18fig4" data-label="Figs. 18.4A and B"><div class="title"><span class="item-label">Figs. 18.4A and B</span> Tuberous sclerosis. <bold>A.</bold> Adenoma sebaceum; <bold>B.</bold> Astrocytoma of the optic disc.</div><img alt="Figs. 18.4A and B" src="/MediumImage/333-2.jpg"><div class="additional-markup"></div></div>
<p class=""><a name="page334"></a><span class="pageBreak"></span><span class="pageNumbers"><span class="bottomPage">334</span></span></p>
<div class="figure" id="ch18fig5" data-label="Fig. 18.5"><div class="title"><span class="item-label">Fig. 18.5</span> Angiomatosis retinae.</div><img alt="Fig. 18.5" src="/MediumImage/334-1.jpg"><div class="additional-markup"></div></div>
<div class="figure" id="ch18fig6" data-label="Fig. 18.6"><div class="title"><span class="item-label">Fig. 18.6</span> Sturge-Weber's syndrome.</div><img alt="Fig. 18.6" src="/MediumImage/334-2.jpg"><div class="additional-markup"></div></div>
<ul style="list-style-type: bullet">
<li><p class="">The main symptoms are decreased visual acuity and a <span class="italic">white pupillary reflex</span>.</p></li>
<li><p class=""><span class="italic">Ophthalmoscopically,</span> yellowish-white exudative patches are seen behind the retinal blood vessels. The blood vessels may have a tortuous course with aneurysms, fusiform dilatations, and loop formations. Hemorrhage in the vitreous may occur subsequently. Eventually, there may be detachment of retina with iritis, cataract and glaucoma.</p></li>
<li><p class="">Treatment is frequently ineffective in established cases, but early photocoagulation or cryotherapy is helpful.</p></li>
</ul>
</div>
</div><div class="section" id="ch18lev1sec6"><h1 class="title">RETINOPATHY OF PREMATURITY (<a href="#ch18fig8" class="ulink-inter">FIG. 18.8</a>)</h1>
<ul style="list-style-type: bullet">
<li><p class="">It is a bilateral abnormality with retinal neovascularization.</p></li>
<li><p class="">It occurs some weeks after birth, in premature infants (less than 1,500 g birth weight), who have been given high concentration of oxygen during the first 10 days of life.</p></li>
<li><p class="">The earliest signs are dilatation of the retinal veins, and the appearance of hazy white patches in the peripheral retina.</p></li>
<li><p class="">This is due to neovascularization in the retina itself which hubs into the vitreous.</p></li>
</ul>
<div class="figure" id="ch18fig7" data-label="Figs. 18.7A and B"><div class="title"><span class="item-label">Figs. 18.7A and B</span> Coats’ disease. <bold>A.</bold> White pupillary reflex; <bold>B.</bold> Fundus picture.</div><img alt="Figs. 18.7A and B" src="/MediumImage/334-3.jpg"><div class="additional-markup"></div></div>
<p class=""><a name="page335"></a><span class="pageBreak"></span><span class="pageNumbers"><span class="bottomPage">335</span></span></p>
<div class="figure" id="ch18fig8" data-label="Fig. 18.8"><div class="title"><span class="item-label">Fig. 18.8</span> Retinopathy of prematurity.</div><img alt="Fig. 18.8" src="/MediumImage/335-1.jpg"><div class="additional-markup"></div></div>
<ul style="list-style-type: bullet">
<li><p class="">This is followed by the development of fibrous tissue which eventually proliferates to form a continuous mass behind the lens, appearing as a type of pseudo-retinoblastoma (pseudoglioma).</p></li>
<li><p class="">In many cases the retina gets detached, and of course, the vision is lost.</p></li>
</ul>
<div class="sidebar">
<h2 class="title">Pathogenesis</h2>
<p class=""><ul style="list-style-type: bullet">
<li><p class="">Retinal vascularization is only completed by the end of full-term gestation, and the retina anterior to the equator (especially that of the upper temporal quadrant) being the last to develop its vessels.</p></li>
<li><p class="">In prematures, these immature vessels may be occluded by high oxygen concentration. On return to normal atmospheric air, there is intense new vessels formation at the border of these ischemic areas.</p></li>
<li><p class="">Milder forms of disorder result in tractional bands in the upper temporal quadrant, producing an ectopic macula or dragged optic disc.</p></li>
</ul></p>
<p class=""><span class="italic">Retinopathy of prematurity (ROP) stages:</span> To describe the fundus findings at the junction between the vascularized and avascular retina.</p>
<p class=""><ul style="list-style-type: bullet">
<li><p class="">Stage 1 = a faint demarcation line</p></li>
<li><p class="">Stage 2 = an elevated ridge</p></li>
<li><p class="">Stage 3 = extraretinal fibrovascular tissue</p></li>
<li><p class="">Stage 4 = subtotal retinal detachment</p></li>
<li><p class="">Stage 5 = total retinal detachment</p></li>
<li><p class="">In addition, <span class="italic">plus disease</span> may be present at any stage. It describes a significant level of vascular dilation and tortuosity observed at the posterior retinal vessels.</p></li>
</ul></p>
</div>
<div class="section" id="ch18lev2sec6"><h2 class="title">Treatment</h2>
<ul style="list-style-type: bullet">
<li><p class="">In 80% of infants, the retinopathy of prematurity will regress spontaneously.</p></li>
<li><p class="">Treatment is required, only when the definite progressive lesion are noted in the vitreous:
<ul style="list-style-type: square">
<li><p class="">Intravitreal injection of anti-VEGF may reduce the area of neovascularization.</p></li>
<li><p class="">Photocoagulation or cryotherapy to ablate the avascular immature retina.</p></li>
<li><p class="">Scleral buckling for retinal detachment.</p></li>
<li><p class=""><span class="italic">Vitamin E</span> (100 mg/kg/day) may protect the susceptible infants.</p></li>
</ul></p></li>
</ul>
</div>
<div class="section" id="ch18lev2sec7"><h2 class="title">Prevention</h2>
<ul style="list-style-type: bullet">
<li><p class="">Monitor arterial (umbilical) PaO<sub>2</sub> levels during treatment of asphyxia neonatorum, and it should be preferably between 50–100 mm Hg.</p></li>
<li><p class="">Premature infants (less than 32 weeks) or weighing less than 1,500 g, who have received oxygen therapy, should be screened for retinopathy of prematurity (ROP) in the NICU at the earliest.</p></li>
<li><p class="">Once the signs of retinopathy develop, the child should be reexamined every 3 to 4 months up to the age of 4 years, to learn the progress of the disease.</p></li>
</ul>
</div>
</div><div class="section" id="ch18lev1sec7"><h1 class="title">RETINAL VASCULAR DISORDERS</h1>
<div class="section" id="ch18lev2sec8"><h2 class="title">Retinal Artery Occlusion</h2>
<p class="noindent">The occlusion may affect the central retinal artery occlusion (CRAO) <bold>(<a href="#ch18fig9" class="ulink-inter">Fig. 18.9</a>)</bold> itself, when the entire retina is involved, or a peripheral branch (arteriole), when the effect is localized.</p>
<div class="section" id="ch18lev3sec5"><h3 class="title">Etiology</h3>
<ul style="list-style-type: bullet">
<li><p class="">Emboli from the carotid artery, e.g., atherosclerotic plaques in older patient</p></li>
<li><p class="">Emboli from valvular heart disease in young patient</p></li>
<li><p class="">Thrombus from arteriolosclerosis</p></li>
<li><p class="">Hypertension</p></li>
<li><p class="">Arteritis.<a name="page336"></a><span class="pageBreak"></span><span class="pageNumbers"><span class="bottomPage">336</span></span></p></li>
</ul>
<div class="figure" id="ch18fig9" data-label="Fig. 18.9"><div class="title"><span class="item-label">Fig. 18.9</span> Central retinal artery occlusion with cherry-red spot.</div><img alt="Fig. 18.9" src="/MediumImage/336-1.jpg"><div class="additional-markup"></div></div>
</div>
<div class="section" id="ch18lev3sec6"><h3 class="title">Symptoms</h3>
<ul style="list-style-type: bullet">
<li><p class="">Painless, unilateral sudden loss of vision.</p></li>
<li><p class=""><span class="italic">Amaurosis fugax</span> (transient sudden loss of vision lasting for few minutes, due to occlusion by minute emboli) may be a premonitory symptom.</p></li>
</ul>
</div>
<div class="section" id="ch18lev3sec7"><h3 class="title">Signs</h3>
<p class="noindent"><span class="italic">Ophthalmoscopically</span>, the fundus shows a typical picture:</p>
<ul style="list-style-type: bullet">
<li><p class="">Larger arteries are thread-like, and the smaller arterioles are invisible.</p></li>
<li><p class="">Veins are almost normal.</p></li>
<li><p class="">Within a few hours, the retina loses its transparency, and becoming opaque and milky-white, especially around the posterior pole.</p></li>
<li><p class="">A day or two later, a <span class="italic">cherry-red spot</span> appears at the fovea, since the vascular choroid is visible underneath. It is beautifully seen against strong contrast of the cloudy-white background <bold>(<a href="#ch18fig9" class="ulink-inter">Fig. 18.9</a>)</bold>.</p></li>
</ul>
<div class="sidebar">
<p class="">A <span class="italic">cherry-red spot</span> is also seen in:</p>
<p class=""><ul style="list-style-type: bullet">
<li><p class="">Blunt injury (Berlin's edema of the macula),</p></li>
<li><p class="">Tay-Sach's disease,</p></li>
<li><p class="">Niemann-Pick disease,</p></li>
<li><p class="">Sandhoff's disease, and</p></li>
<li><p class="">Quinine amblyopia.</p></li>
</ul></p>
</div>
<ul style="list-style-type: bullet">
<li><p class="">When the obstruction is incomplete, the blood flow is partially restored. In that case, gentle pressure upon the globe may break up the column of venous blood into red-beads which move in a jerky fashion—the <span class="italic">cattle-track</span> appearance.</p></li>
<li><p class="">After a week or so, the retina resumes its normal ophthalmoscopic appearance, but the optic nerve becomes atrophic and appears white.</p></li>
<li><p class="">The vision is no perception of light (PL), and there is no direct pupillary reaction.</p></li>
<li><p class=""><span class="italic">In obstruction of a branch of the retinal artery,</span> the occlusion is usually at a bifurcation, and invariably due to embolism. An atheromatous embolus may be visible as a pale refractile body within the artery <span class="italic">(Hollenhorst plaque)</span>, and the distal area of the retina that the vessel supplies, becomes edematous. A sectorial scotoma corresponding to the affected area is detected in visual field charting.</p></li>
</ul>
</div>
<div class="section" id="ch18lev3sec8"><h3 class="title">Diagnosis</h3>
<p class="noindent">It depends on the history, since the patient is very rarely seen during an acute attack. All the patient of <span class="italic">amaurosis fugax</span> should be thoroughly investigated for <span class="italic">cardiovascular problems</span>.</p>
</div>
<div class="section" id="ch18lev3sec9"><h3 class="title">Treatment</h3>
<p class="noindent">It is only effective, if reported within the first few hours of such an occlusion.</p>
<ul style="list-style-type: bullet">
<li><p class="">Immediate intermittent digital message to the globe.</p></li>
<li><p class="">Intravenous acetazolamide, if available.</p></li>
<li><p class="">Inhalation of 5% CO<sub>2</sub> and 95% O<sub>2</sub> mixture for 10 min may be helpful.</p></li>
<li><p class="">Paracentesis of the anterior chamber.</p></li>
<li><p class="">Retrobulbar injection of acetylcholine may produce vasodilatation.</p></li>
<li><p class="">Anticoagulants, as intravenous heparin.</p></li>
</ul>
</div>
</div>
<div class="section" id="ch18lev2sec9"><h2 class="title">Prognosis</h2>
<ul style="list-style-type: bullet">
<li><p class="">As the patient usually presents after few hours, the most frequent result of an occlusion of central retinal artery, however, is blindness.<a name="page337"></a><span class="pageBreak"></span><span class="pageNumbers"><span class="bottomPage">337</span></span></p></li>
</ul>
<div class="figure" id="ch18fig10" data-label="Fig. 18.10"><div class="title"><span class="item-label">Fig. 18.10</span> Central retinal artery occlusion— macular sparing due to patent cilioretinal artery.</div><img alt="Fig. 18.10" src="/MediumImage/337-1.jpg"><div class="additional-markup"></div></div>
<ul style="list-style-type: bullet">
<li><p class="">No return of macular vision is anticipated if the obstruction has lasted over 6 hours.</p></li>
<li><p class="">Where a cilioretinal artery is present (about 25% of cases), blood from the choroid will reach the posterior pole, preserving a useful island of vision which often includes the macular vision <bold>(<a href="#ch18fig10" class="ulink-inter">Fig. 18.10</a>)</bold>.</p></li>
</ul>
</div>
</div><div class="section" id="ch18lev1sec8"><h1 class="title">RETINAL VEIN OCCLUSION</h1>
<p class="noindent">Retinal vein occlusion may involve the central retinal vein which causes immediate severe loss of vision, or a branch retinal vein which results in partial loss of vision, depending on the affected region drained by the vein.</p>
<div class="section" id="ch18lev2sec10"><h2 class="title">Predisposing Factors</h2>
<ul style="list-style-type: bullet">
<li><p class=""><span class="italic">Age:</span> Sixth and seventh decades.</p></li>
<li><p class=""><span class="italic">Systemic hypertension:</span> The vein is compressed by a thickened artery where the two shares a common adventitia (at the arteriovenous crossing).</p></li>
<li><p class=""><span class="italic">Raised intraocular pressure:</span> Patients with primary open-angle glaucoma (POAG) or ocular hypertension are at increased risk of central retinal vein occlusion (CRVO), but no correlation with branch retinal vein occlusion (BRVO).</p></li>
<li><p class=""><span class="italic">Diabetes:</span> Increased risk of CRVO/BRVO.</p></li>
<li><p class=""><span class="italic">Hyperviscosity syndrome:</span> As in chronic leukemia and polycythemia vera (hypercellularity of blood): In macroglobulinemia and cryoglobulinemia (change in plasma proteins) or obstructive pulmonary diseases (COPD).</p></li>
<li><p class=""><span class="italic">Periphlebitis</span> as in sarcoidosis and Behcet's disease.</p></li>
</ul>
<div class="sidebar">
<p class="">Three basic mechanisms involved both in CRVO and BRVO are:</p>
<p class=""><ol style="list-style-type: decimal">
<li><p class="">External compression on the vein,</p></li>
<li><p class="">Venous stasis, and</p></li>
<li><p class="">Degenerative diseases of the venous endothelium.</p></li>
</ol></p>
</div>
</div>
</div><div class="section" id="ch18lev1sec9"><h1 class="title">CENTRAL RETINAL VENOUS OCCLUSION (<a href="#ch18fig10" class="ulink-inter">FIG. 18.10</a>)</h1>
<div class="section" id="ch18lev2sec11"><h2 class="title">Types</h2>
<p class="noindent">There are two main types of CRVO:</p>
<ol style="list-style-type: decimal">
<li><p class=""><span class="italic">Nonischemic CRVO (<a href="#ch18fig11" class="ulink-inter">Fig. 18.11</a>):</span> It is also referred as venous stasis retinopathy or partial CRVO. This accounts for 75% of cases.</p></li>
<li><p class=""><span class="italic">Ischemic CRVO (<a href="#ch18fig12" class="ulink-inter">Fig. 18.12</a>):</span> It is also called complete CRVO, this accounts for the remaining 25% of cases.</p></li>
</ol>
<div class="figure" id="ch18fig11" data-label="Fig. 18.11"><div class="title"><span class="item-label">Fig. 18.11</span> Non-ischemic central retinal venous occlusion.</div><img alt="Fig. 18.11" src="/MediumImage/337-2.jpg"><div class="additional-markup"></div></div>
<p class=""><a name="page338"></a><span class="pageBreak"></span><span class="pageNumbers"><span class="bottomPage">338</span></span></p>
<div class="figure" id="ch18fig12" data-label="Fig. 18.12"><div class="title"><span class="item-label">Fig. 18.12</span> Ischemic central retinal venous occlusion.</div><img alt="Fig. 18.12" src="/MediumImage/338-1.jpg"><div class="additional-markup"></div></div>
<div class="section" id="ch18lev3sec10"><h3 class="title">Nonischemic Central Retinal Venous Occlusion</h3>
<ul style="list-style-type: bullet">
<li><p class=""><span class="italic">Clinical features</span>
<ul style="list-style-type: square">
<li><p class="">Visual acuity is slightly or moderately reduced.</p></li>
<li><p class="">Relative afferent pupillary defect (Marcus-Gunn pupil) is usually mild, indicating mild retinal ischemia.</p></li>
</ul></p></li>
<li><p class=""><span class="italic">Ophthalmoscopically</span>
<ul style="list-style-type: square">
<li><p class="">Mild tortuosity and dilatation of all branches of the central retinal vein.</p></li>
<li><p class=""><span class="italic">Dot/blot and flame-shaped hemorrhages</span>, are seen throughout all four quadrants and most numerous in the periphery.</p></li>
<li><p class="">Cotton-wool exudates are usually absent.</p></li>
<li><p class="">Mild to moderate swelling of the optic disc.</p></li>
<li><p class="">Macular edema may or may not be present.</p></li>
</ul></p></li>
<li><p class=""><span class="italic">Fluorescein angiography:</span> It shows venous stasis but with good retinal capillary perfusion.</p></li>
<li><p class=""><span class="italic">Prognosis:</span> In 50% of cases, the retinopathy resolves, and visual acuity returns to normal or near normal. The permanent impairment of vision is due to chronic macular edema.</p></li>
<li><p class=""><span class="italic">Treatment:</span> No specific treatment is required except to treat the predisposing factor, if any. Treatment is required for chronic macular edema as described in page no 341.</p></li>
</ul>
</div>
<div class="section" id="ch18lev3sec11"><h3 class="title">Ischemic Central Retinal Venous Occlusion</h3>
<ul style="list-style-type: bullet">
<li><p class=""><span class="italic">Clinical features</span>
<ul style="list-style-type: square">
<li><p class="">Marked reduction in visual acuity.</p></li>
<li><p class="">Relative afferent pupillary defect marked.</p></li>
</ul></p></li>
<li><p class=""><span class="italic">Ophthalmoscopically</span>
<ul style="list-style-type: square">
<li><p class="">Marked tortuosity and engorgement of the retinal veins.</p></li>
<li><p class="">Massive superficial and deep hemorrhages throughout the fundus.</p></li>
<li><p class="">Cotton-wool exudates are common.</p></li>
<li><p class="">Optic disc is swollen and hyperemic.</p></li>
<li><p class="">Macular edema and hemorrhages.</p></li>
</ul></p></li>
</ul>
<p class="indent">This appearance is sometimes called <span class="italic">blood and thunder</span> fundus.</p>
<ul style="list-style-type: bullet">
<li><p class=""><span class="italic">Fluorescein angiography</span> in early stage is not useful because of hemorrhages, but in less severe cases or in late stage, there are extensive areas of capillary non-perfusion.</p></li>
<li><p class=""><span class="italic">Course and prognosis:</span> About 50% of eyes develop rubeosis iridis and neovascular glaucoma within 3 months of the initial occlusion <span class="italic">(90-days glaucoma)</span>. A small percentage of eyes develop pre-retinal or vitreous hemorrhage, secondary to NVD and/or NVE.</p></li>
<li><p class=""><span class="italic">Treatment</span>
<ul style="list-style-type: square">
<li><p class="">Patients should be followed-up closely for rubeosis iridis, as prompt treatment in early cases, by panretinal photocoagulation (PRP) (or cryoapplication if the media is hazy), prevents the subsequent development of neovascular glaucoma.</p></li>
<li><p class="">The management of established neovascular glaucoma is discussed in <a href="/9789356963825/chapter/ch16" class="ulink-exter">Chapter 16</a>.</p></li>
</ul></p></li>
</ul>
</div>
</div>
</div><div class="section" id="ch18lev1sec10"><h1 class="title">BRANCH RETINAL VENOUS OCCLUSION</h1>
<p class="noindent">It <bold>(<a href="#ch18fig13" class="ulink-inter">Fig. 18.13</a>)</bold> may occur near the optic disc and involves a major quadrant of the retina, or it may occur at a peripheral crossing with an artery.<a name="page339"></a><span class="pageBreak"></span><span class="pageNumbers"><span class="bottomPage">339</span></span></p>
<div class="figure" id="ch18fig13" data-label="Fig. 18.13"><div class="title"><span class="item-label">Fig. 18.13</span> Branch retinal venous occlusion.</div><img alt="Fig. 18.13" src="/MediumImage/339-1.jpg"><div class="additional-markup"></div></div>
<p class="noindent">Blockage of the superior temporal vein frequently involves the macula.</p>
<ul style="list-style-type: bullet">
<li><p class=""><span class="italic">Symptoms:</span> These depend on the location of the occlusion. Visual loss is marked, if the superior temporal branch is occluded. <span class="italic">Ophthalmoscopically</span> the affected part of the retina, drained by the obstructed vein shows:
<ul style="list-style-type: square">
<li><p class="">Dilated and tortuous veins</p></li>
<li><p class="">Flame-shaped, and dot and blot hemorrhage in the affected quadrant</p></li>
<li><p class="">Retinal edema and cotton-wool spots.</p></li>
</ul></p></li>
<li><p class=""><span class="italic">Course and prognosis:</span> Following a major branch retinal vein occlusion, visual acuity is initially reduced due to macular hemorrhage and edema.
<ul style="list-style-type: square">
<li><p class="">Within 6 months, 50% of eyes develop efficient collaterals and visual acuity returns to 6/12, or better. However, complications may arise from vascular leakage and capillary nonperfusion.</p></li>
<li><p class="">Two most important vision-threatening complications are:</p>
<ol style="list-style-type: decimal">
<li><p class="">Macular edema</p></li>
<li><p class="">Vitreous hemorrhage due to neovascularization.</p></li>
</ol></li>
<li><p class="">Secondary neovascular glaucoma occurs very rarely.</p></li>
</ul></p></li>
<li><p class=""><span class="italic">Treatment</span>
<ul style="list-style-type: square">
<li><p class="">Fundus fluorescein angiography to know the macular non-perfusion, or macular edema with good perfusion, and also to identify the <span class="italic">collateral vessels</span> (because they must not be treated by laser).</p></li>
<li><p class="">For macular edema, grid photo-coagulation with argon laser or double- frequency yttrium aluminum garnet (YAG) (532) laser may be helpful.</p></li>
<li><p class=""><span class="italic">Role of anti-VEGF:</span> They are available to treat macular edema due to BRVO including ranibizumab (Lucentis, bevacizumab (Avastin), and aflibercept (Eylea).</p></li>
<li><p class="">For neovascularization following BRVO, the eye should be treated by scatter argon laser photocoagulation, in order to prevent vitreous hemorrhage.</p></li>
</ul></p></li>
</ul>
</div><div class="section" id="ch18lev1sec11"><h1 class="title">CENTRAL SEROUS RETINOPATHY</h1>
<p class="noindent">Central serous retinopathy (CSR), also called central serous chorioretinopathy (CSCR) <bold>(<a href="#ch18fig14" class="ulink-inter">Figs. 18.14A and B</a>)</bold> is characterized by sudden edema of the macular area, which typically affects the young adult males due to unknown cause. It is basically a localized retinal detachment, and caused by exudation from the parafoveal or choroidal capillaries.</p>
<p class="noindent"><span class="italic">Symptoms</span></p>
<ul style="list-style-type: bullet">
<li><p class="">Sudden onset of blurring of vision in one eye.</p></li>
<li><p class="">Black fixed spot (a positive scotoma) at the center of the visual field.</p></li>
<li><p class="">Metamorphopsia.</p></li>
</ul>
<p class="noindent"><span class="italic">Signs</span></p>
<ul style="list-style-type: bullet">
<li><p class="">Visual acuity reduced to 6/9 to 6/18, and often correctable to 6/6 with weak plus lens. This is due to elevation of neurosensory retina which gives rise to an acquired hypermetropia.</p></li>
<li><p class=""><span class="italic">Ophthalmoscopically,</span> macula appears as an oval or circular dark swelling, larger than the size of the optic disc, which is surrounded by a glistening <span class="italic">ring-reflex</span>.<a name="page340"></a><span class="pageBreak"></span><span class="pageNumbers"><span class="bottomPage">340</span></span></p></li>
</ul>
<div class="figure" id="ch18fig14" data-label="Figs. 18.14A and B"><div class="title"><span class="item-label">Figs. 18.14A and B</span> <bold>A.</bold> Central serous retinopathy; <bold>B.</bold> Ink-blot pattern on fundus fluorescein angiography.</div><img alt="Figs. 18.14A and B" src="/MediumImage/340-1.jpg"><div class="additional-markup"></div></div>
</div><div class="section" id="ch18lev1sec12"><h1 class="title">FUNDUS FLUORESCEIN ANGIOGRAPHY</h1>
<p class="noindent">Fundus fluorescein angiography (FFA) is helpful for a definitive diagnosis of CSR. Two patterns are seen on FFA:</p>
<ol style="list-style-type: decimal">
<li><p class=""><span class="italic">Ink-blot pattern:</span> Small hyperfluorescent spot, gradually increases in size.</p></li>
<li><p class=""><span class="italic">Smoke-stack pattern (<a href="#ch18fig15" class="ulink-inter">Figs. 18.15A to C</a>):</span> A small hyperfluorescent spot, ascends vertically like a smoke-stack, and gradually spreads laterally taking on a mushroom or umbrella configuration.</p></li>
</ol>
<p class="noindent"><span class="italic">Prognosis</span></p>
<ul style="list-style-type: bullet">
<li><p class="">Eighty to ninety percent cases of CSR undergo spontaneous resolution, and the visual acuity returns to normal or near normal, within 4–12 weeks.</p></li>
<li><p class="">Mild metamorphopsia or micropsia may persist for a longer period.</p></li>
<li><p class="">About 40% of patients develop recurrent attacks.</p></li>
</ul>
<p class="noindent"><span class="italic">Treatment</span></p>
<ul style="list-style-type: bullet">
<li><p class="">In majority of the cases, no treatment is required except reassurance.</p></li>
<li><p class="">Argon laser or double-frequency YAG (532) laser photocoagulation to the site of leakage may be considered in some cases:
<ul style="list-style-type: square">
<li><p class="">Recurrent CSR with visual loss.</p></li>
<li><p class="">If the vision in fellow eye is permanently reduced due to previous attacks of CSR.</p></li>
<li><p class="">If the duration is more than 4 months.</p></li>
<li><p class="">In presence of turbid subretinal fluid.</p></li>
</ul></p></li>
</ul>
<div class="figure" id="ch18fig15" data-label="Figs. 18.15A to C"><div class="title"><span class="item-label">Figs. 18.15A to C</span> Central serous retinopathy—smoke-stack pattern on fundus fluorescein angiography.</div><img alt="Figs. 18.15A to C" src="/MediumImage/340-2.jpg"><div class="additional-markup"></div></div>
<p class=""><a name="page341"></a><span class="pageBreak"></span><span class="pageNumbers"><span class="bottomPage">341</span></span></p>
</div><div class="section" id="ch18lev1sec13"><h1 class="title">CYSTOID MACULAR EDEMA (<a href="#ch18fig16" class="ulink-inter">FIG. 18.16</a>)</h1>
<p class="noindent">Cystoid macular edema (CME) is an accumulation of fluid in the outer plexiform (Henle's) layer and inner nuclear layer of the retina, in the macular region.</p>
<div class="section" id="ch18lev2sec12"><h2 class="title">Etiology</h2>
<p class="noindent">Cystoid macular edema is a very common macular disorder that has many diverse causes:</p>
<ul style="list-style-type: bullet">
<li><p class=""><span class="italic">Irvine-Gass syndrome:</span> Probably, it is the most common cause of CME, which occurs as a common complication of cataract extraction, especially when associated with vitreous prolapse. The majority of the cases are transient and have little clinical significance.</p></li>
<li><p class=""><span class="italic">Non-proliferative diabetic retinopathy:</span> CME is an important cause of visual impairment among diabetics. It is also called diabetic macular edema or DME.</p></li>
<li><p class=""><span class="italic">Retinal vein occlusion:</span> Chronic CME may occur following CRVO or BRVO.</p></li>
<li><p class=""><span class="italic">Pars planitis</span> and <span class="italic">acute iridocyclitis</span>.</p></li>
<li><p class=""><span class="italic">Retinitis pigmentosa:</span> Typical CME may be present up to 70% of eyes with retinitis pigmentosa.</p></li>
<li><p class=""><span class="italic">Epinephrine:</span> Not used nowadays. CME may develop in aphakic eyes treated with epinephrine for open-angle glaucoma (epinephrine maculopathy).</p></li>
</ul>
</div>
<div class="section" id="ch18lev2sec13"><h2 class="title">Clinical Features</h2>
<ul style="list-style-type: bullet">
<li><p class="">Visual acuity is often reduced to 6/60.</p></li>
<li><p class=""><span class="italic">Ophthalmoscopy</span> shows an irregularity and blurring of the foveal reflex.</p></li>
<li><p class="">The macula is wrinkled, edematous, and may show multiple small cystic changes.</p></li>
<li><p class="">In long-standing cases, there is formation of lamellar holes at the fovea with irreversible damage to central vision <bold>(<a href="#ch18fig17" class="ulink-inter">Fig. 18.17</a>)</bold>.</p></li>
</ul>
<p class="noindent"><span class="italic">Fluorescein angiography</span> demonstrates leakage of the dye from the perifoveal capillaries, and accumulation within the macular region. The accumulation of dye in the outer plexiform layer, with its radial arrangement of fibers (Henle's layer) is responsible for the typical <span class="italic">flower-petal</span> <bold>(<a href="#ch18fig18" class="ulink-inter">Fig. 18.18</a>)</bold> or <span class="italic">spoke</span>-<span class="italic">pattern</span> of CME on FFA.</p>
</div>
<div class="section" id="ch18lev2sec14"><h2 class="title">Treatment</h2>
<ul style="list-style-type: bullet">
<li><p class="">The edema is usually self-limiting and improvement is spontaneous.</p></li>
<li><p class="">Systemic steroids are often used in vascular or inflammatory conditions.</p></li>
<li><p class="">Systemic steroids, sub-Tenon long-acting steroid, and nonsteroidal anti-inflammatory agents (systemic or local) are helpful in postoperative cases.</p></li>
</ul>
<div class="figure" id="ch18fig16" data-label="Fig. 18.16"><div class="title"><span class="item-label">Fig. 18.16</span> Cystoid macular edema.</div><img alt="Fig. 18.16" src="/MediumImage/341-1.jpg"><div class="additional-markup"></div></div>
<div class="figure" id="ch18fig17" data-label="Fig. 18.17"><div class="title"><span class="item-label">Fig. 18.17</span> Macular hole formation.</div><img alt="Fig. 18.17" src="/MediumImage/341-2.jpg"><div class="additional-markup"></div></div>
<p class=""><a name="page342"></a><span class="pageBreak"></span><span class="pageNumbers"><span class="bottomPage">342</span></span></p>
<div class="figure" id="ch18fig18" data-label="Fig. 18.18"><div class="title"><span class="item-label">Fig. 18.18</span> Cystoid macular edema—flower-petal pattern on fundus fluorescein angiography.</div><img alt="Fig. 18.18" src="/MediumImage/342-1.jpg"><div class="additional-markup"></div></div>
<ul style="list-style-type: bullet">
<li><p class="">Intravitreal anti-VEGF injection, such as ranibizumab (Lucentis, Accentrix); bevacizumab (Avastin), or aflibercept (Eylea) is very useful in chronic macular edema.</p></li>
</ul>
</div>
</div><div class="section" id="ch18lev1sec14"><h1 class="title">AGE-RELATED MACULAR DEGENERATION</h1>
<p class="noindent">Age-related macular degeneration (AMD) is a bilateral disease, characterized by formation of subretinal neovascular membranes (SRNVMs) or choroidal neovascular membranes (CNVMs) at the macula. It is one of the leading causes of blindness in the Western world.</p>
<p class="indent">Histopathologically drusen, retinal pigment epithelial degeneration and/or atrophy, SRNVMs, retinal pigment epithelium (RPE) and sensory retinal detachment due to subretinal hemorrhage, and disciform scars at the macula, are the different manifestations of the disease in different stages.</p>
<div class="section" id="ch18lev2sec15"><h2 class="title">Drusen</h2>
<p class="noindent">Drusens or colloid bodies are the most frequent clinical manifestation of aging and are present in about 70% of people after the age of 50 years.</p>
<div class="section" id="ch18lev3sec12"><h3 class="title">Clinical Features</h3>
<p class="noindent">They appear as small, discrete, yellow-white, slightly elevated spots at the posterior poles of both fundi. With advancing age, they increase in size and number.</p>
<p class="indent">Secondary calcification in long-standing lesions gives them a glistening-white appearance.</p>
</div>
<div class="section" id="ch18lev3sec13"><h3 class="title">Classification</h3>
<ul style="list-style-type: bullet">
<li><p class=""><span class="italic">Hard drusen (nodular) (<a href="#ch18fig19" class="ulink-inter">Fig. 18.19</a>):</span> It appears as small, discrete yellowish-white nodules.</p></li>
<li><p class=""><span class="italic">Soft drusen (<a href="#ch18fig20" class="ulink-inter">Fig. 18.20</a>):</span> It has indistinct edges, are larger than hard drusens, and frequently become confluent.</p></li>
<li><p class=""><span class="italic">Diffuse drusen</span> (confluent): It represents a widespread abnormality of RPE.</p></li>
<li><p class=""><span class="italic">Calcified drusen:</span> It has glistening-white appearance with conspicuous margin.</p></li>
</ul>
<div class="figure" id="ch18fig19" data-label="Fig. 18.19"><div class="title"><span class="item-label">Fig. 18.19</span> Central hard drusen.</div><img alt="Fig. 18.19" src="/MediumImage/342-2.jpg"><div class="additional-markup"></div></div>
<div class="figure" id="ch18fig20" data-label="Fig. 18.20"><div class="title"><span class="item-label">Fig. 18.20</span> Central soft drusen.</div><img alt="Fig. 18.20" src="/MediumImage/342-3.jpg"><div class="additional-markup"></div></div>
<p class=""><a name="page343"></a><span class="pageBreak"></span><span class="pageNumbers"><span class="bottomPage">343</span></span></p>
</div>
<div class="section" id="ch18lev3sec14"><h3 class="title">Histopathology</h3>
<p class="noindent">Drusens consist of focal aggregation of hyaline material located between the basal lamina of the RPE and inner collagenous layer of the Bruch's membrane.</p>
<ul style="list-style-type: bullet">
<li><p class="">Localized thickening and thinning of the Bruch's membrane.</p></li>
<li><p class="">Variable degrees of RPE atrophy and depigmentation.</p></li>
<li><p class="">Degenerative changes of the retinal receptors.</p></li>
</ul>
</div>
</div>
<div class="section" id="ch18lev2sec16"><h2 class="title">Fluorescein Angiography</h2>
<ul style="list-style-type: bullet">
<li><p class=""><span class="italic">Retinal pigment epithelium window defects</span> appear as multiple hyperfluorescent spots.</p></li>
<li><p class=""><span class="italic">Staining of the drusens</span> by the dye, which may persist for a long time.</p></li>
</ul>
<div class="sidebar">
<h2 class="title">Drusen and AMD</h2>
<p class=""><ul style="list-style-type: bullet">
<li><p class="">The exact role of drusen in the pathogenesis of ARMD is still not clear.</p></li>
<li><p class="">But a significant number of elderly patients with drusens may develop impairment of vision due to ARMD.</p></li>
<li><p class="">Increased risk of subsequent visual loss in patient with confluent drusens, specially if one eye has already developed visual loss from ARMD.</p></li>
</ul></p>
</div>
</div>
<div class="section" id="ch18lev2sec17"><h2 class="title">Types of Age-related Macular Degeneration</h2>
<p class="noindent">They are of two main types:</p>
<ol style="list-style-type: decimal">
<li><p class="">Non-exudative (dry) AMD</p></li>
<li><p class="">Exudative (wet) AMD.</p></li>
</ol>
<div class="section" id="ch18lev3sec15"><h3 class="title">Non-exudative (Dry) Age-related Macular Degeneration</h3>
<ul style="list-style-type: bullet">
<li><p class="">It is the most common type and is due to a slow and progressive atrophy of RPE and photoreceptors.</p></li>
<li><p class="">Progressive loss of vision for several months to years.</p></li>
<li><p class=""><span class="italic">Clinically,</span> it appears as sharp circumscribed areas of RPE atrophy with varying degrees of loss of choriocapillaris. In late stage, the larger choroidal vessels become visible within the atrophic areas.</p></li>
</ul>
<p class="noindent"><span class="italic">Treatment</span></p>
<ul style="list-style-type: bullet">
<li><p class="">There are no definite medical treatments for dry AMD at this time.</p></li>
<li><p class=""><span class="italic">Lifestyle changes:</span> It can slow down the process or contribute to the development and progress of AMD.</p></li>
<li><p class="">Antioxidant medication that included vitamin C, vitamin E, beta carotene (or vitamin A), and zinc can slow the progression of the disease by 25%.</p></li>
<li><p class="">Changing the diet which includes more fruits and vegetable, choosing healthy unsaturated fats, such as olive oil, refined grains and adding fish with high omega-3 fatty acids and also cessation of smoking habit.</p></li>
<li><p class=""><span class="italic">Low vision rehabilitation:</span> The use of magnifying devices, e.g., binoculars or telescopes can often improve vision in macular degeneration to allow for reading or watching of television.</p></li>
<li><p class="">Use of Tablet digital devices or large smart phone—as reading device or to watch video.</p></li>
<li><p class="">Miniature implantable telescope may help to improve the central vision. It involves surgical removal of crystalline lens and replace it with a miniature telescope. This is followed by an extensive training program.</p></li>
</ul>
</div>
<div class="section" id="ch18lev3sec16"><h3 class="title">Exudative (Wet) Age-related Macular Degeneration</h3>
<ul style="list-style-type: bullet">
<li><p class="">It is also referred to as <span class="italic">neovascular</span> or wet AMD and is less common than non-exudative type <bold>(<a href="#ch18fig21" class="ulink-inter">Fig. 18.21</a>)</bold>.</p></li>
<li><p class="">This is a more serious form, and the patient may lose all central vision within a few weeks. <span class="italic">Amslers grid test</span> <bold>(<a href="#ch18fig22" class="ulink-inter">Figs. 18.22A to C</a>)</bold> is convenient and accurate way to detect AMD in early stage.</p></li>
<li><p class="">Two important features of exudative AMD are <span class="italic">detachment</span> of the RPE and <span class="italic">choroidal neovascularization</span>.</p></li>
<li><p class=""><span class="italic">RPE detachment</span> appears as sharply circumscribed dome-shaped elevation with ophthalmoscope.<a name="page344"></a><span class="pageBreak"></span><span class="pageNumbers"><span class="bottomPage">344</span></span></p></li>
</ul>
<div class="figure" id="ch18fig21" data-label="Fig. 18.21"><div class="title"><span class="item-label">Fig. 18.21</span> Age-related macular degeneration—exudative type.</div><img alt="Fig. 18.21" src="/MediumImage/344-1.jpg"><div class="additional-markup"></div></div>
<ul style="list-style-type: bullet">
<li><p class="">Subretinal neovascular membranes (SRNVMs), consisting of proliferations of fibrovascular tissue, begin to grow from the choriocapillaris → through the defects of the Bruch's membrane → into the sub-RPE space → and later into the subretinal space.</p></li>
<li><p class=""><span class="italic">Clinically,</span> SRNVMs are undetectable in early stage. But later, they appear as gray-green elevated lesions in the macular region.</p></li>
<li><p class=""><span class="italic">Fluorescein angiography</span> plays an important role in the detection and localization of SRNVMs in relation to foveal avascular zone (FAZ).</p></li>
<li><p class=""><span class="italic">Sequelae of exudative—AMD</span>
<ul style="list-style-type: square">
<li><p class="">Hemorrhagic detachment of the RPE and neurosensory retina</p></li>
<li><p class="">Vitreous hemorrhage</p></li>
<li><p class="">Disciform scarring of the macula</p></li>
<li><p class="">Exudative retinal detachment.</p></li>
</ul></p></li>
</ul>
<div class="section" id="ch18lev4sec1"><h4 class="title">Treatment</h4>
<p class="noindent">Wet macular degeneration cannot be cured. If diagnosed early, treatment may help slow progress of wet macular degeneration and reduce the amount of vision lost.</p>
<p class="noindent">There are three main treatment options for wet AMD:</p>
<ol style="list-style-type: decimal">
<li><p class="">Anti-VEGF (vascular endothelial growth factor) medication to prevent the growth of new blood vessels in the eye.</p></li>
<li><p class="">Photodynamic therapy (PDT) to treat foveal abnormal vessels.</p></li>
<li><p class="">Laser surgery to destroy abnormal blood vessels in the eye.</p></li>
</ol>
<ul style="list-style-type: bullet">
<li><p class=""><span class="italic">Anti-VEGF:</span> Intravitreal injection are considered the first-line treatment for all stages of wet macular degeneration. They include <span class="italic">(see</span> anti-VEGF in <a href="/9789356963825/chapter/ch5" class="ulink-exter">Chapter 5</a>):
<ul style="list-style-type: square">
<li><p class="">Bevacizumab (Avastin)</p></li>
<li><p class="">Ranibizumab (Lucentis)</p></li>
<li><p class="">Pegaptanib (Macugen)</p></li>
<li><p class="">Aflibercept (Eylea).</p>
<p class=""><div class="figure" id="ch18fig22" data-label="Figs. 18.22A to C"><div class="title"><span class="item-label">Figs. 18.22A to C</span> Amsler grid test in ARMD, total number of square—20 × 20 in the chart. One square denotes 10 from the central part of fovea. Central diamond-shaped black spot represents foveola; <bold>A.</bold> Normal grid pattern; <bold>B.</bold> Distorted or missing pattern and <bold>C.</bold> Dark central spot.</div><img alt="Figs. 18.22A to C" src="/MediumImage/344-2.jpg"><div class="additional-markup"></div></div></p></li>
</ul></p></li>
<li><p class=""><a name="page345"></a><span class="pageBreak"></span><span class="pageNumbers"><span class="bottomPage">345</span></span><span class="italic">Photodynamic therapy:</span> Using cold laser light to activate an injected medication called, verteporfin to prevent progression of SRNVMs. PDT is still used to treat some cases of Wet AMD sometimes in conjunction with anti-VEGF injection.</p></li>
<li><p class=""><span class="italic">Photocoagulation:</span> Using an Argon (blue-green) laser to destroy abnormal extrafoveal SRNVMs outside the area of FAZ. Only a small number of patients are eligible for this procedure, as most patients have growth in the area of the fovea, which cannot be treated by laser.</p></li>
<li><p class="">Counseling of the patients regarding continued therapy.</p></li>
</ul>
</div>
</div>
</div>
</div><div class="section" id="ch18lev1sec15"><h1 class="title">RETINITIS PIGMENTOSA (<a href="#ch18fig23" class="ulink-inter">FIGS. 18.23A TO C</a>)</h1>
<p class="noindent">Retinitis pigmentosa (RP) is a group of hereditary diseases, characterized by progressive night blindness and constricted visual fields.</p>
<div class="section" id="ch18lev2sec18"><h2 class="title">Typical Retinitis Pigmentosa</h2>
<p class="noindent">Typical RP is a bilateral symmetrical diffuse pigmentary retinal dystrophy, predominantly affecting the rods.</p>
<div class="section" id="ch18lev3sec17"><h3 class="title">Inheritance</h3>
<ul style="list-style-type: bullet">
<li><p class=""><span class="italic">Autosomal recessive:</span> Most common.</p></li>
<li><p class=""><span class="italic">Autosomal dominant:</span> Benign nature.</p></li>
</ul>
</div>
<div class="section" id="ch18lev3sec18"><h3 class="title">Pathogenesis</h3>
<ul style="list-style-type: bullet">
<li><p class="">Degeneration of the rods and cones.</p></li>
<li><p class="">Migration of pigments into the retina.</p></li>
<li><p class="">Degenerated ganglion cells and their axons are replaced by neuroglial tissue.</p></li>
<li><p class="">Attenuation of the blood vessels.</p></li>
<li><p class="">Atrophy of the optic disc.</p></li>
</ul>
</div>
<div class="section" id="ch18lev3sec19"><h3 class="title">Clinical Features</h3>
<ul style="list-style-type: bullet">
<li><p class=""><span class="italic">Symptoms:</span> Include night blindness and progressive visual field defect.</p></li>
<li><p class=""><span class="italic">Signs:</span> The classical triad of RP are:
<ul style="list-style-type: square">
<li><p class="">Bony-spicule pigmentation</p></li>
<li><p class="">Arteriolar attenuation</p></li>
<li><p class="">Waxy-pallor of the optic disc.</p></li>
</ul></p></li>
<li><p class="">Pigmentary changes are typically perivascular, and have a bone-spicule appearance, which are observed mostly at the equatorial region of the retina.</p></li>
<li><p class="">In late stages of the disease, the unmasking of the larger choroidal vessels (due to pigment migration), gives the fundus a tessellated appearance.</p></li>
<li><p class=""><span class="italic">Macular lesions</span>
<ul style="list-style-type: square">
<li><p class=""><span class="italic">Cystoid macular edema</span> may be present up to 70% of the patients with RP.</p></li>
<li><p class="">Cellophane maculopathy.</p></li>
<li><p class="">Atrophic maculopathy.</p></li>
</ul></p></li>
</ul>
</div>
<div class="section" id="ch18lev3sec20"><h3 class="title">Investigations</h3>
<p class="noindent">They are helpful in early stages:</p>
<ul style="list-style-type: bullet">
<li><p class=""><span class="italic">Electroretinography (ERG):</span> Markedly sub-normal in amplitude.</p></li>
<li><p class=""><span class="italic">Electrooculography (EOG):</span> Absence of light peak.</p></li>
<li><p class=""><span class="italic">Visual field:</span> Initially shows annular or ring-like scotoma. But ultimately, the progressive constriction of the visual field leaves only a tiny island of central vision, which may be lost eventually <bold>(<a href="#ch18fig24" class="ulink-inter">Fig. 18.24</a>)</bold>.</p></li>
</ul>
<div class="figure" id="ch18fig23" data-label="Figs. 18.23A to C"><div class="title"><span class="item-label">Figs. 18.23A to C</span> <bold>A.</bold> Retinitis pigmentosa; <bold>B.</bold> Retinitis pigmentosa with cystoid macular edema; <bold>C.</bold> Retinitis punctate albicans.</div><img alt="Figs. 18.23A to C" src="/MediumImage/345-1.jpg"><div class="additional-markup"></div></div>
<p class=""><a name="page346"></a><span class="pageBreak"></span><span class="pageNumbers"><span class="bottomPage">346</span></span></p>
<div class="figure" id="ch18fig24" data-label="Fig. 18.24"><div class="title"><span class="item-label">Fig. 18.24</span> Ring scotoma in retinitis pigmentosa.</div><img alt="Fig. 18.24" src="/MediumImage/346-1.jpg"><div class="additional-markup"></div></div>
<div class="figure" id="ch18fig25" data-label="Fig. 18.25"><div class="title"><span class="item-label">Fig. 18.25</span> Laurence-Moon-Biedl syndrome. Note the toes (polydactyly).</div><img alt="Fig. 18.25" src="/MediumImage/346-2.jpg"><div class="additional-markup"></div></div>
</div>
</div>
<div class="section" id="ch18lev2sec19"><h2 class="title">Atypical Retinitis Pigmentosa</h2>
<ul style="list-style-type: bullet">
<li><p class=""><span class="italic">Retinitis punctata albescens:</span> This is characterized by multiple scattered white dots, mostly between the posterior pole and the equator. Other findings are similar to typical RP.</p></li>
<li><p class=""><span class="italic">Retinitis pigmentosa sine pigmento:</span> The typical pigmentary changes appear very late, while the presence of arteriolar attenuation and waxy-pallor of the disc with subnormal ERG, confirm the diagnosis.</p></li>
<li><p class=""><span class="italic">Sectorial retinitis pigmentosa:</span> Involvement of only one quadrant (usually nasal), or one half (usually inferior) of the fundus.</p></li>
<li><p class=""><span class="italic">Pericentric retinitis pigmentosa:</span> It is similar to typical RP, except that the pigmentary changes are confined to pericentral area, sparing the periphery.</p></li>
</ul>
</div>
<div class="section" id="ch18lev2sec20"><h2 class="title">Systemic Associations of Retinitis Pigmentosa</h2>
<ul style="list-style-type: bullet">
<li><p class=""><span class="italic">Laurence-Moon-Biedl syndrome (Bardet Biedl) (<a href="#ch18fig25" class="ulink-inter">Fig. 18.25</a>):</span> Autosomal recessive; RP, mental retardation, polydactyly, obesity and hypogonadism.</p></li>
<li><p class=""><span class="italic">Bassen-Kornzweig syndrome (abetalipoproteinemia):</span> Autosomal recessive; RP, ataxia, acanthocytosis and fat malabsorption. Jejunal biopsy is diagnostic.</p></li>
<li><p class=""><span class="italic">Refsum's syndrome:</span> Autosomal recessive; RP, peripheral neuropathy, cerebellar ataxia, elevated cerebrospinal fluid-proteins (CSF-proteins), deafness and ichthyosis. It is due to defective metabolism of <span class="italic">phytanic acid</span> which accumulates in the body.</p></li>
<li><p class=""><span class="italic">Usher's syndrome:</span> Autosomal recessive; RP and sensorineural deafness.</p></li>
<li><p class=""><span class="italic">Cockayne's syndrome:</span> Autosomal recessive; RP, dwarfism, ‘bird-like’ facies, flexion contracture of the limbs, mental retardation, ataxia and premature aging.</p></li>
<li><p class=""><span class="italic">Kearns-Sayre syndrome:</span> The classical <span class="italic">triad</span> of RP, chronic progressive external ophthalmoplegia (ocular myopathy) and heart block; a rare mitochondrial DNA (mtDNA) deletion syndrome.<a name="page347"></a><span class="pageBreak"></span><span class="pageNumbers"><span class="bottomPage">347</span></span></p></li>
<li><p class=""><span class="italic">Friedreich's ataxia:</span> Autosomal recessive; RP, posterior column disease, cerebellar ataxia, nystagmus and subaortic stenosis.</p></li>
<li><p class=""><span class="italic">Neuropathy, ataxia, and retinitis pigmentosa (NARP) syndrome:</span> It is a rare hereditary condition. It is related to changes in mitochondrial DNA (mutations in the MT-ATP6 gene).</p></li>
</ul>
</div>
<div class="section" id="ch18lev2sec21"><h2 class="title">Treatment</h2>
<ul style="list-style-type: bullet">
<li><p class="">No definite treatment is available for RP patients.</p></li>
<li><p class="">However, there are therapies available to maximize their vision with refraction and low-visual aids (LVA).</p></li>
<li><p class="">They should be examined annually for visual field testing and ERG evaluations. Often after this, the patients may be reassured that the changes are slow. Additionally, regular examinations can ensure appropriate time to seek community and legal assistance.</p></li>
<li><p class=""><span class="italic">Medications</span>
<ul style="list-style-type: square">
<li><p class="">Antioxidants and omega-3 fatty acid; or vitamin A (15,000 IU/day) may be useful in long-term to slow the progression.</p></li>
<li><p class=""><span class="italic">Acetazolamide:</span> It may be useful in macular edema in the later stages of RP.</p></li>
<li><p class="">Some medications have potential adverse effects in RP like, isotretinoin, vitamin E (400 IU) and sildenafil (viagra).</p></li>
<li><p class="">It may worsen night vision and ERG response.</p></li>
</ul></p></li>
<li><p class=""><span class="italic">Cataract extraction:</span> Often beneficial in RP with posterior subcapsular opacity with an improvement by 2 lines on Snellen chart.</p></li>
<li><p class=""><span class="italic">Miscellaneous:</span> Dietary plan as in Refsum disease, audiology in Usher's syndrome, etc.</p></li>
<li><p class="">Stem cells transplantation and retinal pros-thesis (photoconducting chip on retinal surface) are being used in clinical trials in patients with RP, AMD and Stargardt disease.</p></li>
<li><p class=""><span class="italic">Gene therapy:</span> It is also under investigation.</p></li>
<li><p class=""><span class="italic">Counseling:</span> Genetic testing and counseling to know the mode of inheritance. Counseling can also help the patients for their future plans, such as pregnancy, job choices, medical treatments and psychological boost up.</p></li>
</ul>
</div>
</div><div class="section" id="ch18lev1sec16"><h1 class="title">RETINAL DETACHMENT</h1>
<ul style="list-style-type: bullet">
<li><p class=""><span class="italic">Retinal detachment (RD):</span> It is the separation of the sensory retina from the retinal pigmentary epithelium (which represent the two layers of the primary optic vesicle) by subretinal fluid (SRF).</p></li>
<li><p class=""><span class="italic">Retinoschisis:</span> It is the splitting of the sensory retina into two layers.</p></li>
<li><p class=""><span class="italic">Retinal break:</span> It is the full-thickness defect in the sensory retina.
<ul style="list-style-type: square">
<li><p class=""><span class="italic">Hole:</span> It is a small retinal break (usually circular) without any vitreous traction.</p></li>
<li><p class=""><span class="italic">Tear:</span> It is a retinal break (usually horse-shoe-shaped) with the tractional element. A tear is more dangerous than a hole.</p></li>
</ul></p></li>
<li><p class=""><span class="italic">Syneresis:</span> It is the contraction of vitreous gel which separates its liquid from solid components.</p></li>
<li><p class=""><span class="italic">Synchysis:</span> It is the liquefaction of the vitreous gel.</p></li>
<li><p class=""><span class="italic">Choroidal detachment</span>: It is an effusion of fluid into the suprachoroidal space.</p></li>
</ul>
<div class="section" id="ch18lev2sec22"><h2 class="title">Classification</h2>
<ul style="list-style-type: bullet">
<li><p class="">Rhegmatogenous (primary) (Greek word <span class="italic">rhegma</span> means a break).</p></li>
<li><p class="">Non-rhegmatogenous (secondary)
<ul style="list-style-type: square">
<li><p class="">Tractional</p></li>
<li><p class="">Exudative.</p></li>
</ul></p></li>
</ul>
<div class="section" id="ch18lev3sec21"><h3 class="title">Rhegmatogenous</h3>
<p class="noindent">Subretinal fluid, derived from the fluid vitreous gains access into the subretinal space through a retinal break. Rhegmatogenous RD may be traumatic or spontaneous.</p>
</div>
<div class="section" id="ch18lev3sec22"><h3 class="title">Non-rhegmatogenous</h3>
<ul style="list-style-type: bullet">
<li><p class=""><span class="italic">Tractional:</span> The sensory retina is pulled away from the RPE by the vitreoretinal traction membranes. Two important <a name="page348"></a><span class="pageBreak"></span><span class="pageNumbers"><span class="bottomPage">348</span></span>causes of tractional RD are proliferative retinopathies, and penetrating ocular injury. The source of SRF is unknown.</p></li>
<li><p class=""><span class="italic">Exudative:</span> SRF, derived from the choroid gains access to the subretinal space through the damaged RPE. Exudative RD may be due to choroidal tumors and inflammation.</p></li>
</ul>
</div>
</div>
</div><div class="section" id="ch18lev1sec17"><h1 class="title">RHEGMATOGENOUS RETINAL DETACHMENT (<a href="#ch18fig26" class="ulink-inter">FIGS. 18.26</a> AND <a href="#ch18fig27" class="ulink-inter">18.27</a>)</h1>
<div class="section" id="ch18lev2sec23"><h2 class="title">Etiology</h2>
<ul style="list-style-type: bullet">
<li><p class=""><span class="italic">Incidence</span>: 1 in 10,000 population each year, and bilateral in 10% of the cases.</p></li>
<li><p class=""><span class="italic">Trauma</span>: Most common in young adult males.</p></li>
<li><p class=""><span class="italic">Myopia:</span> Over 40% of all RDs occur in myopic subjects. This is due to higher incidence of lattice degeneration, liquefaction of the vitreous, and posterior vitreous detachment.</p></li>
<li><p class=""><span class="italic">Peripheral retinal degeneration:</span> Lattice is the most important degeneration directly related to RD, and is found more commonly in myopes over—3.0D.</p></li>
</ul>
<div class="sidebar">
<h2 class="title">Peripheral retinal degeneration</h2>
<p class="">About 60% of all retinal breaks develop in the peripheral retina that shows specific changes. These lesions may be associated with a spontaneous hole formation, or they may predispose to retinal tear formation. The important predisposing degenerations are:</p>
<p class=""><ul style="list-style-type: bullet">
<li><p class=""><span class="italic">Lattice degeneration:</span> It is present in about 8% of general population, and 40% of eyes with myopia and RD. It is characterized by white arborizing lines, arranged in a lattice pattern occurring in the upper peripheral fundus between the equator and posterior border of the vitreous base, with long axis parallel to the ora serrata.</p></li>
<li><p class=""><span class="italic">Snail-track degeneration:</span> It consists of sharply, demarcated bands of tightly packed snowflakes with a white frost-like appearance.</p></li>
<li><p class=""><span class="italic">White-with-pressure:</span> It is a grayish-white appearance of the retina, induced by indenting the sclera (in case of normal fundus, scleral indentation induces a reddish elevation).</p></li>
<li><p class=""><span class="italic">White-without-pressure:</span> It is an exaggeration of the above phenomenon, and is present without scleral indentation.</p></li>
<li><p class=""><span class="italic">Focal pigment clumps:</span> It may be found with a retinal tear.</p></li>
</ul></p>
<p class="noindent"><span class="italic">Other benign degeneration are:</span></p>
<p class=""><ul style="list-style-type: bullet">
<li><p class=""><span class="italic">Peripheral (micro) cystoid degeneration:</span> It may be a constant finding in old age with increasing severity. This is not itself causally related to RD.</p></li>
<li><p class=""><span class="italic">Paving-stone degeneration:</span> It consists of yellowish-white areas of chorioretinal atrophy (present in 25% of normal eyes).</p></li>
<li><p class=""><span class="italic">Snowflakes:</span> They are minute, yellowish- white dots which are scattered diffusely in the periphery.</p></li>
</ul></p>
</div>
<ul style="list-style-type: bullet">
<li><p class=""><span class="italic">Cataract surgery:</span> It was more common with intracapsular cataract extraction, particularly if there had been vitreous loss. The incidence following extracapsular cataract extraction (ECCE) is less, possibly because the intact posterior capsule acts as a support to the vitreous, lessening its pull on the retina. It is also common after repeated needling in congenital cataract or after YAG-laser capsulotomy.</p></li>
</ul>
<div class="sidebar">
<h2 class="title">Pathogenesis of rhegmatogenous</h2>
<p class=""><ul style="list-style-type: bullet">
<li><p class="">The breaks responsible for RD, are caused by interplay between vitreoretinal traction, and an underlying weakness of the peripheral retina.</p></li>
<li><p class="">30% of horse-shoe tears proceed to RD within 6 weeks, and often within a few hours.</p></li>
<li><p class="">If the retinal operculum becomes completely detached from the tear to lie separated from the retina, the risk of RD is reduced.</p></li>
<li><p class="">Once the fluid (from liquefied vitreous) accumulates between the sensory retina and RPE, the retina becomes detached.</p></li>
<li><p class="">As the subretinal fluid (SRF) accumulates, it tends to gravitate downward.</p></li>
<li><p class="">The final shape of the RD is being determined by the position of the break, and the anatomical limits of the disc and ora serrata.<a name="page349"></a><span class="pageBreak"></span><span class="pageNumbers"><span class="bottomPage">349</span></span></p></li>
</ul></p>
</div>
<div class="figure" id="ch18fig26" data-label="Figs. 18.26A to D"><div class="title"><span class="item-label">Figs. 18.26A to D</span> Rhegmatogenous retinal detachment. <bold>A.</bold> Horse-shoe tear; <bold>B.</bold> Hole; <bold>C.</bold> Retinal dialysis; <bold>D.</bold> Accumulation of subretinal fluid.</div><img alt="Figs. 18.26A to D" src="/MediumImage/349-1.jpg"><div class="additional-markup"></div></div>
<div class="figure" id="ch18fig27" data-label="Figs. 18.27A and B"><div class="title"><span class="item-label">Figs. 18.27A and B</span> Rhegmatogenous retinal detachment.</div><img alt="Figs. 18.27A and B" src="/MediumImage/349-2.jpg"><div class="additional-markup"></div></div>
</div>
<div class="section" id="ch18lev2sec24"><h2 class="title">Symptoms</h2>
<ul style="list-style-type: bullet">
<li><p class="">The classical premonitory symptoms reported in 60% patients with RD, are:
<ul style="list-style-type: square">
<li><p class=""><span class="italic">Photopsia:</span> It is a flash of light and this is due to vitreoretinal traction.</p></li>
<li><p class=""><span class="italic">Floaters:</span> Which may appear as large ring, small black spots or cobwebs.</p></li>
</ul></p></li>
<li><p class=""><span class="italic">Visual field defect:</span> It is due to the spread of SRF posterior to the equator, and is perceived by the patient as a black curtain.<a name="page350"></a><span class="pageBreak"></span><span class="pageNumbers"><span class="bottomPage">350</span></span></p></li>
<li><p class=""><span class="italic">Loss of central vision:</span> It is due to involvement of the fovea.</p></li>
</ul>
</div>
<div class="section" id="ch18lev2sec25"><h2 class="title">Signs</h2>
<p class="noindent"><span class="italic">In fresh RD:</span></p>
<ul style="list-style-type: bullet">
<li><p class="">Relative afferent pupillary defect (Marcus-Gunn pupil) in eyes with extensive RD.</p></li>
<li><p class="">Intraocular pressure is low.</p></li>
<li><p class="">Mild anterior uveitis.</p></li>
<li><p class=""><span class="italic">Posterior segment:</span> Indirect ophthalmoscopy is more important.
<ul style="list-style-type: square">
<li><p class="">Detached retina is slightly opaque, convex and corrugated in appearance (due to intraretinal edema), with loss of underlying choroidal pattern.</p></li>
<li><p class="">Detached retina undulates freely with ocular movements.</p></li>
<li><p class="">There is no shifting of fluid.</p></li>
<li><p class="">Breaks appear as red areas (holes or tears) of discontinuities mainly in the peripheral retina.</p></li>
<li><p class="">Vitreous shows <span class="italic">tobacco dust</span> in the anterior vitreous, with posterior vitreous detachment.</p></li>
</ul></p></li>
</ul>
<p class="noindent"><span class="italic">In long-standing RD:</span></p>
<ul style="list-style-type: bullet">
<li><p class="">Retinal thinning.</p></li>
<li><p class="">Subretinal demarcation lines.</p></li>
<li><p class="">Secondary intraretinal cysts.</p></li>
<li><p class="">Multiple opaque strands of subretinal fibrosis.</p></li>
<li><p class="">Subsequently, proliferative vitreoretinopathy (PVR) develops.</p></li>
<li><p class="">If untreated, the vast majority of RDs become total, and eventually give rise to complicated cataract, chronic uveitis, hypotony and eventually phthisis bulbi.</p></li>
</ul>
</div>
<div class="section" id="ch18lev2sec26"><h2 class="title">Investigations</h2>
<ul style="list-style-type: bullet">
<li><p class=""><span class="italic">Indirect ophthalmoscopy</span> is most important, and both eyes should be examined. Scleral indentation is necessary to enhance visualization of the extreme peripheral retina.</p></li>
<li><p class="">Fundus drawing with appropriate color codes on a fundus chart.</p></li>
<li><p class=""><span class="italic">Ultra-wide fundus photography (OPTOS):</span> is helpful to detect area retinal pathology.</p></li>
<li><p class=""><span class="italic">Slit-lamp examination with three-mirror contact lens:</span> It has central contact lens with 3 mirrors placed in the cone, each at different angle of inclination, to view different parts of the retina:
<ol style="list-style-type: decimal">
<li><p class="">Central contact lens for posterior pole and vitreous</p></li>
<li><p class="">Mirror inclined at 73°—area around posterior pole</p></li>
<li><p class="">Mirror inclined at 67°—equatorial retina</p></li>
<li><p class="">Mirror inclined at 59°—anterior peripheral retina including ora serrata and pars plana</p>
<p class="">The image is virtual and erect.</p></li>
</ol></p></li>
<li><p class=""><span class="italic">Ultrasonography (USG):</span> Both A-scan and B-scan are helpful when the media is hazy.</p></li>
</ul>
</div>
<div class="section" id="ch18lev2sec27"><h2 class="title">Treatment (<a href="#ch18fig28" class="ulink-inter">Figs. 18.28A to C</a>)</h2>
<p class="noindent">The treatment of rhegmatogenous RD is essentially surgical, and should be immediate, once the diagnosis has been established.</p>
<p class="noindent">The patient should take rest in recumbent position as much as possible.</p>
<ul style="list-style-type: bullet">
<li><p class="">There are several methods of treating a detached retina, each of which depends on retinal breaks. The three general principles are:
<ol style="list-style-type: decimal">
<li><p class="">To find out the retinal breaks</p></li>
<li><p class="">To seal the breaks</p></li>
<li><p class="">To relieve present (and future) vitreo-retinal traction.</p></li>
</ol></p></li>
<li><p class=""><span class="italic">Sealing the retinal breaks:</span> It is required in any form of rhegmatogenous RD surgery— retinal breaks are closed by producing an area of chorioretinitis in the region of the defect, so that, the adhesions between the edge of the break and the RPE will seal the opening.</p></li>
<li><p class="">The chorioretinal reaction may be produced by cryosurgery (cryoretinopexy) at −70°C, or diathermy to the sclera, or by laser photocoagulation.<a name="page351"></a><span class="pageBreak"></span><span class="pageNumbers"><span class="bottomPage">351</span></span></p></li>
</ul>
<div class="figure" id="ch18fig28" data-label="Figs. 18.28A to C"><div class="title"><span class="item-label">Figs. 18.28A to C</span> Treatment of rhegmatogenous retinal detachment. <bold>A.</bold> Preoperative appearance; <bold>B.</bold> Encirclage (360°); <bold>C.</bold> Postoperative appearance.</div><img alt="Figs. 18.28A to C" src="/MediumImage/351-1.jpg"><div class="additional-markup"></div></div>
<p class="indent">Three types of retinal detachment surgery are practiced:</p>
<ol style="list-style-type: decimal">
<li><p class=""><span class="italic">Vitrectomy:</span> Pars plana vitrectomy (PPV) is the most commonly performed operation treatment for retinal detachment. It works by removing the vitreous from the eye and replacing it with either a gas (SF6 or C3F8) or silicone oil. This helps in reattaching retina.</p>
<p class="">Small dissolving sutures are used to close the wound. It is also possible to perform such surgery without the use of stitches, using 23G or 25G instruments.</p>
<p class="">After the procedure, the patient requires positioning of the head for a while, so the gas bubble settles in the correct position.</p>
<ul style="list-style-type: square">
<li><p class=""><span class="italic">Advantages</span> of using gas in this surgery is that there is no myopic shift after the operation and gas is absorbed within a 2–3 weeks. There is less chance of future vitreoretinal traction. Silicone oil is more commonly used in cases associated with PVR changes. Silicone oil, if filled needs to be removed 3–6 months after surgery depending on surgeon's preference.</p></li>
<li><p class=""><span class="italic">Disadvantage:</span> Vitrectomy always leads to more rapid progression of a cataract in the operated eye. Emulsified silicone oil may sometime seep into the anterior chamber, causing keratopathy and inverse hypopyon.</p></li>
</ul></li>
<li><p class=""><span class="italic">Scleral buckling:</span> It is a surgical procedure to create an inward indentation of the sclera and the choroid. Scleral buckling is achieved by inserting a plomb (exoplant), which is usually a solid silicone band or a silicone sponge, and sutured firmly to the sclera.</p>
<ul style="list-style-type: square">
<li><p class=""><span class="italic">Radially-oriented</span> plombage is most effective in sealing an isolated horse-shoe tear, and <span class="italic">circumferential</span> plombage (cerclage operation) is indicated when multiple holes are present parallel to the equator.</p></li>
<li><p class=""><span class="italic">Subretinal fluid drainage:</span> It is customary to drain SRF by inserting a fine needle through the sclera and choroid, into the subretinal space, and allowing SRF to drain away.</p></li>
</ul></li>
<li><p class=""><span class="italic">Pneumatic retinopexy:</span> If the retinal detachment is relatively small and uncomplicated, a procedure called pneumatic retinopexy may be used. This involves injecting a small bubble of SF6 or C3F8 gas into the eye, and may be followed by laser photocoagulation or cryoretinopexy to create scar tissue around the break. The patient's head is then positioned so that the bubble rests against the retinal hole. Patients may have to keep their heads tilted for several days to keep the gas bubble in contact with the retinal hole. The bubble is slowly absorbed into the eye over the following weeks:</p>
<ul style="list-style-type: square">
<li><p class="">This strict positioning requirement makes the treatment of the retinal holes and detachments that occurs in the lower part of the eyeball impractical.<a name="page352"></a><span class="pageBreak"></span><span class="pageNumbers"><span class="bottomPage">352</span></span></p>
<p class=""><div class="figure" id="ch18fig29" data-label="Figs. 18.29A and B"><div class="title"><span class="item-label">Figs. 18.29A and B</span> Tractional retinal detachment (note the concave appearance of the detached retina).</div><img alt="Figs. 18.29A and B" src="/MediumImage/352-1.jpg"><div class="additional-markup"></div></div></p>
<p class=""><div class="figure" id="ch18fig30" data-label="Fig. 18.30"><div class="title"><span class="item-label">Fig. 18.30</span> Tractional retinal detachment.</div><img alt="Fig. 18.30" src="/MediumImage/352-2.jpg"><div class="additional-markup"></div></div></p></li>
<li><p class="">Pneumatic retinopexy has significantly lower success rates compared to scleral buckle surgery and vitrectomy.</p></li>
<li><p class=""><span class="italic">When an expansile gas is used with vitrectomy or for pneumoretinopexy, there is restriction of another surgery under GA or on flying.</span></p></li>
<li><p class=""><span class="italic">Prognosis</span>: About 80–90% of RDs can be reattached, often with excellent visual results with immediate surgery, specially when the macula is not involved. As, a detachment in the other eye occurs later in a high proportion of cases, a thorough retinal examination (indirect ophthalmoscopy), and prophylactic cryoretinopexy or laser photocoagulation is done, if there is any retinal break.</p></li>
</ul></li>
</ol>
</div>
</div><div class="section" id="ch18lev1sec18"><h1 class="title">TRACTIONAL RETINAL DETACHMENT (<a href="#ch18fig29" class="ulink-inter">FIGS. 18.29</a> AND <a href="#ch18fig30" class="ulink-inter">18.30</a>)</h1>
<div class="section" id="ch18lev2sec28"><h2 class="title">Symptoms</h2>
<ul style="list-style-type: bullet">
<li><p class="">Photopsia and floaters are usually absent, because the vitreoretinal traction develops slowly.</p></li>
<li><p class="">Slow and progressive loss of visual field.</p></li>
</ul>
</div>
<div class="section" id="ch18lev2sec29"><h2 class="title">Signs</h2>
<ul style="list-style-type: bullet">
<li><p class="">Retinal breaks are usually absent.</p></li>
<li><p class="">Detachment configuration is concave or tent-like. The highest elevation of retina occurs at the site of vitreoretinal traction.</p></li>
<li><p class="">Mobility of the detached area is severely reduced.</p></li>
<li><p class="">Subretinal demarcation lines are absent.</p></li>
</ul>
</div>
</div><div class="section" id="ch18lev1sec19"><h1 class="title">EXUDATIVE RETINAL DETACHMENT (<a href="#ch18fig31" class="ulink-inter">FIGS. 18.31</a> AND <a href="#ch18fig32" class="ulink-inter">18.32</a>)</h1>
<div class="section" id="ch18lev2sec30"><h2 class="title">Symptoms</h2>
<ul style="list-style-type: bullet">
<li><p class="">Floaters are present occasionally and sometimes, the patient describes it as a black curtain in specific quadrant of visual field.</p></li>
<li><p class="">Photopsia is absent, as there is no vitreoretinal traction.</p></li>
<li><p class="">Sudden and rapid loss of visual field.</p></li>
</ul>
</div>
<div class="section" id="ch18lev2sec31"><h2 class="title">Signs</h2>
<ul style="list-style-type: bullet">
<li><p class="">Retinal breaks are absent.<a name="page353"></a><span class="pageBreak"></span><span class="pageNumbers"><span class="bottomPage">353</span></span></p></li>
</ul>
<div class="figure" id="ch18fig31" data-label="Figs. 18.31A and B"><div class="title"><span class="item-label">Figs. 18.31A and B</span> Exudative retinal detachment (note the bullous appearance of the detached retina).</div><img alt="Figs. 18.31A and B" src="/MediumImage/353-1.jpg"><div class="additional-markup"></div></div>
<div class="figure" id="ch18fig32" data-label="Fig. 18.32"><div class="title"><span class="item-label">Fig. 18.32</span> Exudative retinal detachment—bullous detachment.</div><img alt="Fig. 18.32" src="/MediumImage/353-2.jpg"><div class="additional-markup"></div></div>
<ul style="list-style-type: bullet">
<li><p class="">Detachment configuration is convex. The detached retina is smooth, noncorrugated and bullous, and it may even touch the back of the lens.</p></li>
<li><p class=""><bold>Shifting of fluid</bold> is <span class="italic">the hallmark of exudative RD</span>. The SRF responds to the force of gravity, and detaches the area under which it accumulates.</p></li>
<li><p class="">Other associated ocular features—e.g., choroidal tumors, or systemic features (e.g., rheumatoid arthritis, Harada's disease, toxemia of pregnancy, etc.) may be present.</p></li>
</ul>
</div>
</div><div class="section" id="ch18lev1sec20"><h1 class="title">HYPERTENSIVE RETINOPATHY</h1>
<ul style="list-style-type: bullet">
<li><p class="">In systemic hypertension, it is important to consider two aspects separately—the severity and the duration.</p></li>
<li><p class="">The <span class="italic">severity of hypertension</span> is reflected by the degree of hypertensive vascular changes and retinopathy.</p></li>
<li><p class="">The <span class="italic">duration of hypertension</span> is reflected by the degree of arteriolosclerosis changes and retinopathy.</p></li>
<li><p class="">The <span class="italic">primary response</span> of the retinal arterioles to systemic hypertension is <span class="italic">narrowing</span>, and it occurs only in young individual in its pure form.</p></li>
<li><p class="">But, the degree of response in aged patient, also depends on the amount of preexisting involutional sclerosis.</p></li>
<li><p class="">So, the grading of retinal changes in hypertension has caused confusion, because of the replacement fibrosis of arterial hypertension, and that of aging are identical.</p></li>
</ul>
<div class="section" id="ch18lev2sec32"><h2 class="title">Pathogenesis</h2>
<ul style="list-style-type: bullet">
<li><p class="">Systemic chronic hypertension → narrowing of the retinal arterioles → retinal ischemia → hypoxia → increased capillary permeability → focal retinal edema, retinal hemorrhage and hard exudates.</p></li>
<li><p class="">Hard exudates deposit around the fovea in the Henle's layer, and lead to their radial distribution, in the form of <span class="italic">macular star</span>.</p></li>
<li><p class="">In severe or acute hypertension → obstruction of the precapillary arterioles → fibrinoid necrosis of the axons of nerve-fiber layer → interruption of axoplasmic flow → build-up of transported material within the nerve axons → <span class="italic">cotton-wool spots</span>.<a name="page354"></a><span class="pageBreak"></span><span class="pageNumbers"><span class="bottomPage">354</span></span></p></li>
</ul>
</div>
<div class="section" id="ch18lev2sec33"><h2 class="title">Classification</h2>
<div class="section" id="ch18lev3sec23"><h3 class="title">Keith-Wagner-Barkan</h3>
<p class="noindent">This is traditional and widely cited. It relates only systemic hypertension and arteriolar sclerosis (not for involutional sclerosis).</p>
<ul style="list-style-type: bullet">
<li><p class=""><span class="italic">Grade-1:</span> Mild generalized arteriolar narrowing.</p></li>
<li><p class=""><span class="italic">Grade-2:</span> More narrowing of the arterioles and also focal arteriolar attenuation. Arteriovenous crossing changes (e.g., nicking) present.</p></li>
<li><p class=""><span class="italic">Grade-3:</span> Grade II changes with hemorrhage, cotton-wool spot and exudates.</p></li>
<li><p class=""><span class="italic">Grade-4:</span> All the changes of grade III with papilledema including the neuroretinal edema.</p></li>
</ul>
</div>
<div class="section" id="ch18lev3sec24"><h3 class="title">Scheie's Classification</h3>
<p class="noindent">Here, the retinal changes of hypertension and arteriolar sclerosis are graded separately.</p>
<div class="section" id="ch18lev4sec2"><h4 class="title">Hypertensive features</h4>
<ul style="list-style-type: bullet">
<li><p class=""><span class="italic">Normal:</span> No ophthalmoscopic retinal changes.</p></li>
<li><p class=""><span class="italic">Grade-1:</span> Narrowing of smaller retinal arterioles.</p></li>
<li><p class=""><span class="italic">Grade-2:</span> Severe narrowing with localized irregular constriction of the arterioles.</p></li>
<li><p class=""><span class="italic">Grade-3:</span> Narrowing and irregularities of the arterioles, with retinal hemorrhage and exudates.</p></li>
<li><p class=""><span class="italic">Grade-4:</span> All changes in grade-3 along with neuroretinal edema, and/or papilledema <bold>(<a href="#ch18fig33" class="ulink-inter">Figs. 18.33A and B</a>)</bold>.</p></li>
</ul>
</div>
<div class="section" id="ch18lev4sec3"><h4 class="title">Arteriolosclerotic features</h4>
<p class="noindent">These changes develop if the hypertension is present over a period of many years, and are mainly seen in aged individual.</p>
<ul style="list-style-type: bullet">
<li><p class=""><span class="italic">Normal:</span> No sclerotic changes.</p></li>
<li><p class=""><span class="italic">Grade-1:</span> Widening of arteriolar light reflex with simple venous concealment.</p></li>
<li><p class=""><span class="italic">Grade-2:</span> Grade-1 changes with deflection of veins at the arteriovenous crossing (Salus’ sign).</p></li>
<li><p class=""><span class="italic">Grade-3:</span> Grade-2 changes with copper wire arterioles, and marked arteriovenous crossing changes.</p></li>
<li><p class=""><span class="italic">Grade-4:</span> All changes of grade-3 with silver wire arterioles and marked arteriovenous crossing changes. It may be associated with branch vein occlusion.</p></li>
</ul>
<p class="noindent"><span class="italic">Arteriovenous crossing changes may be (<a href="#ch18fig34" class="ulink-inter">Figs. 18.34A to D</a>):</span></p>
<ul style="list-style-type: bullet">
<li><p class="">Banking of the vein where it appears dilated, distal to the crossing <span class="italic">(Bonnet's sign)</span>.</p></li>
<li><p class="">Tapering of the vein on either side of the crossing <span class="italic">(Gunn's sign)</span>.</p></li>
<li><p class="">Right-angled deflection of the vein, which gives the vein as S-shaped bend.</p></li>
</ul>
<p class="noindent"><span class="italic">Associated choroidal changes:</span></p>
<ul style="list-style-type: bullet">
<li><p class="">Severe hypertension may cause fibrinoid necrosis of the choroidal vessels which leads to atrophy of the RPE.</p></li>
</ul>
<div class="figure" id="ch18fig33" data-label="Figs. 18.33A and B"><div class="title"><span class="item-label">Figs. 18.33A and B</span> Hypertensive retinopathy (Grade IV) with macular star.</div><img alt="Figs. 18.33A and B" src="/MediumImage/354-1.jpg"><div class="additional-markup"></div></div>
<p class=""><a name="page355"></a><span class="pageBreak"></span><span class="pageNumbers"><span class="bottomPage">355</span></span></p>
<div class="figure" id="ch18fig34" data-label="Figs. 18.34A to D"><div class="title"><span class="item-label">Figs. 18.34A to D</span> Arteriovenous crossing changes in hypertensive retinopathy.</div><img alt="Figs. 18.34A to D" src="/MediumImage/355-1.jpg"><div class="additional-markup"></div></div>
<ul style="list-style-type: bullet">
<li><p class="">Pigment deposition along the course of occluded choroidal vessels, is called <span class="italic">Seigrist's line</span>.</p></li>
<li><p class="">Irregular scattered bright-yellow spots are also seen, called <span class="italic">Elschnig's spots</span>.</p></li>
<li><p class="">Exudative bullous retinal detachment may occur in severe cases.</p></li>
</ul>
<div class="sidebar">
<h2 class="title">Renal retinopathy</h2>
<p class="">The term describes the retinal changes seen in chronic renal failure. These may mimic a hypertensive retinopathy of Grade-III or IV, but the tendency to exudate formation is marked, specially at the macula.</p>
<p class="indent">The severe <bold>hypertension in eclampsia</bold> may precipitate a florid retinopathy of Grade-IV, often with exudative retinal detachment. This detachment clears rapidly with the termination of pregnancy when the hypertension is under control.</p>
</div>
</div>
</div>
</div>
<div class="section" id="ch18lev2sec34"><h2 class="title">Treatment</h2>
<p class="noindent">The treatment of hypertensive retinopathies is, necessarily, control of hypertension and that of underlying disease.</p>
</div>
</div><div class="section" id="ch18lev1sec21"><h1 class="title">DIABETIC RETINOPATHY</h1>
<ul style="list-style-type: bullet">
<li><p class="">The prevalence of diabetic retinopathy (DR) is about 4–28%, and about 2% of diabetic population is blind as a result of retinopathy.</p></li>
<li><p class="">The <span class="italic">best predictor</span> of diabetic retinopathy is the duration of diabetes. There is no clinically apparent diabetic retinopathy for 5 years after initial diagnosis.</p></li>
<li><p class="">The severity of the diabetic retinopathy, generally parallels the duration of the disease and the adequacy of its control, and not the severity of the diabetes.</p></li>
<li><p class="">The incidence of diabetic retinopathy is more with insulin dependent diabetes mellitus (IDDM) than with non-insulin dependent diabetes mellitus (NIDDM), but the severity of maculopathy is more with NIDDM.</p></li>
<li><p class="">The course and severity of DR are affected by the presence of nephropathy, systemic hypertension, pregnancy, and positive family history of DR.</p></li>
</ul>
<div class="section" id="ch18lev2sec35"><h2 class="title">Pathogenesis</h2>
<ul style="list-style-type: bullet">
<li><p class="">The exact pathogenesis of DR is still not clearly understood.</p></li>
<li><p class="">Diabetic retinopathy is essentially a <span class="italic">microangiopathy</span> which affects the retinal precapillary arterioles, capillaries and venules.</p></li>
<li><p class="">This microangiopathy causes microvascular occlusion and leakage.</p></li>
<li><p class="">Microvascular occlusion → retinal ischemia → retinal hypoxia.</p>
<p class="">Two main effects of retinal hypoxia are neovascularization and arteriovenous shunts formation.</p></li>
<li><p class=""><span class="italic">Microvascular weakness</span> is due to loss of pericytes and damage to the endothelial cells → saccular pouch formation → micro- aneurysm, which may leak.</p></li>
<li><p class=""><span class="italic">Microvascular leakage</span> → increased vascular permeability → hemorrhage and retinal edema.</p></li>
<li><p class=""><span class="italic">Chronic localized retinal edema</span> leads to the deposition of hard exudates at the junction of healthy and edematous retina. The hard exudates are composed of lipoprotein and lipid laden macrophages, and they are typically arranged in a circinate pattern.<a name="page356"></a><span class="pageBreak"></span><span class="pageNumbers"><span class="bottomPage">356</span></span></p></li>
</ul>
<div class="figure" id="ch18fig35" data-label="Fig. 18.35"><div class="title"><span class="item-label">Fig. 18.35</span> Non-proliferative diabetic retinopathy—loop (arrow), dot and blot hemorrhage.</div><img alt="Fig. 18.35" src="/MediumImage/356-1.jpg"><div class="additional-markup"></div></div>
<div class="figure" id="ch18fig36" data-label="Fig. 18.36"><div class="title"><span class="item-label">Fig. 18.36</span> Proliferative diabetic retinopathy—neovascularization elsewhere (NVE).</div><img alt="Fig. 18.36" src="/MediumImage/356-2.jpg"><div class="additional-markup"></div></div>
</div>
<div class="section" id="ch18lev2sec36"><h2 class="title">Classification</h2>
<ul style="list-style-type: bullet">
<li><p class="">Non-proliferative diabetic retinopathy (NPDR) <bold>(<a href="#ch18fig35" class="ulink-inter">Fig. 18.35</a>)</bold></p></li>
<li><p class="">Diabetic maculopathy
<ul style="list-style-type: square">
<li><p class="">Focal</p></li>
<li><p class="">Diffuse</p></li>
<li><p class="">Ischemic</p></li>
</ul></p></li>
<li><p class="">Pre-proliferative diabetic retinopathy</p></li>
<li><p class="">Proliferative diabetic retinopathy (PDR) <bold>(<a href="#ch18fig36" class="ulink-inter">Fig. 18.36</a>)</bold></p></li>
<li><p class="">Advanced diabetic eye diseases
<ul style="list-style-type: square">
<li><p class="">Vitreous hemorrhage</p></li>
<li><p class="">Tractional retinal detachment</p></li>
<li><p class="">Preretinal membrane</p></li>
<li><p class="">Neovascular glaucoma.</p></li>
</ul></p></li>
</ul>
</div>
<div class="section" id="ch18lev2sec37"><h2 class="title">Non-proliferative Diabetic Retinopathy (NPDR)</h2>
<div class="section" id="ch18lev3sec25"><h3 class="title">Clinical Features</h3>
<ul style="list-style-type: bullet">
<li><p class=""><span class="italic">Microaneurysms:</span> They are the most characteristic ocular lesions in diabetics.</p></li>
</ul>
<p class="noindent"><span class="italic">They also occur in:</span></p>
<ul style="list-style-type: square">
<li><p class="">Retinal venous occlusion</p></li>
<li><p class="">Coat's disease</p></li>
<li><p class="">Arterial hypertension</p></li>
<li><p class="">Anemia</p></li>
<li><p class="">Dysproteinemia, etc.</p></li>
</ul>
<p class="indent">Microaneurysms associated with diseases other than diabetes, are located on the arterial side of the capillary, rather than on the venous side at the posterior pole.</p>
<p class="indent">Microaneurysms consist of minute, round or ovoid distensions ranging from 20–200 µ in size, located on the venous side of capillary network at the inner nuclear layer.</p>
<div class="sidebar">
<p class="">The resolving power of the direct ophthalmoscope is about 70–80 µ. Thus, majority of microaneurysms are not seen with the direct ophthalmoscope. They are visible with FFA.</p>
</div>
<p class="noindent">They may be indistinguishable from ‘dot’ hemorrhages.</p>
<ul style="list-style-type: bullet">
<li><p class=""><span class="italic">Dot and blot hemorrhages:</span> They originate from the venous end of the capillaries, and are situated in the inner nuclear layer of the retina.</p></li>
<li><p class=""><span class="italic">Flame-shaped hemorrhages:</span> They are located superficially in the nerve-fiber layer.</p></li>
<li><p class=""><span class="italic">Hard exudates</span> have a yellow-waxy appearance with a distinct margin, and become confluent, and may form a circinate pattern around the macula. They are located between the inner plexiform and inner nuclear layer of the retina.</p></li>
</ul>
</div>
</div>
<div class="section" id="ch18lev2sec38"><h2 class="title">Diabetic Maculopathy</h2>
<p class="noindent">Diabetic maculopathy is the most common cause of visual impairment in patients with <a name="page357"></a><span class="pageBreak"></span><span class="pageNumbers"><span class="bottomPage">357</span></span>diabetic retinopathy, and is more frequent in NIDDM. Maculopathy is of three types—focal, diffuse and ischemic.</p>
<div class="section" id="ch18lev3sec26"><h3 class="title">Focal</h3>
<ul style="list-style-type: bullet">
<li><p class="">Features of NPDR</p></li>
<li><p class="">Macular edema</p></li>
<li><p class="">Hard exudates, may be ring-shaped</p></li>
<li><p class="">Microaneurysms [absent within foveal avascular zone (FAZ)]</p></li>
<li><p class="">Visual acuity is severely impaired</p></li>
<li><p class="">It is caused by leakage from microaneurysms and dilated capillaries</p></li>
<li><p class="">FFA shows—focal area of leakage, but adequate macular capillary perfusion.</p></li>
</ul>
</div>
<div class="section" id="ch18lev3sec27"><h3 class="title">Diffuse</h3>
<ul style="list-style-type: bullet">
<li><p class="">Microaneurysms and hemorrhages</p></li>
<li><p class="">Focal retinal thickening around the macula</p></li>
<li><p class="">Few hard exudates</p></li>
<li><p class="">Cystoid macular edema in long-standing cases. Popularly called diabetic macular edema (DME).</p></li>
<li><p class="">Lamellar hole may result</p></li>
<li><p class="">FFA shows diffuse leakage at the posterior pole with typical flower-petal pattern (as in CME).</p></li>
</ul>
</div>
<div class="section" id="ch18lev3sec28"><h3 class="title">Ischemic</h3>
<ul style="list-style-type: bullet">
<li><p class="">Clinically, it may be similar to those seen in diffuse maculopathy.</p></li>
<li><p class="">Fluorescein angiography is necessary to differentiate it from the diffuse type. FFA shows areas of capillary non-perfusion in the macular and paramacular regions.</p></li>
</ul>
</div>
</div>
<div class="section" id="ch18lev2sec39"><h2 class="title">Pre-proliferative Diabetic Retinopathy</h2>
<p class="noindent">It develops in some eyes, those initially show only non-proliferative retinopathy. The lesions are caused by retinal ischemia <bold>(<a href="#ch18fig36" class="ulink-inter">Fig. 18.36</a>)</bold>.</p>
<ul style="list-style-type: bullet">
<li><p class=""><span class="italic">Cotton-wool patches (soft exudates)</span> are due to capillary occlusion of the nerve fiber layers.</p></li>
<li><p class=""><span class="italic">Intraretinal microvascular abnormalities (IRMA):</span> They are seen adjacent to the areas of capillary closure. IRMA may resemble focal areas of flat retinal neovascularization. The main features of IRMA are intraretinal location, absence of profuse leakage on FFA, and failure to crossover the main retinal vessels.</p></li>
<li><p class="">Venous changes consist of dilatation, beading, looping, and sausage-like segmentation.</p></li>
<li><p class=""><span class="italic">Arteriolar</span> narrowing resembling branch retinal arteriolar occlusion.</p></li>
<li><p class="">Large dark blot hemorrhages due to hemorrhagic retinal infarcts.</p></li>
</ul>
<div class="sidebar">
<h2 class="title">Recent classification of diabetic retinopathy</h2>
<p class=""><ul style="list-style-type: bullet">
<li><p class="">Non-proliferative diabetic retinopathy <bold>(NPDR)</bold></p></li>
<li><p class="">Proliferative diabetic retinopathy <bold>(PDR)</bold></p></li>
</ul></p>
<p class=""><span class="italic">NPDR:</span> The lesions include microaneurysms, small dot and blot hemorrhages, IRMA and cotton wool spots. NPDR is further classified as mild, moderate, severe and very severe NPDR.</p>
<p class=""><ul style="list-style-type: bullet">
<li><p class=""><span class="italic">Mild NPDR:</span> At least one microaneurysms, and also dot and blot or flame-shaped hemorrhages in all four quadrants.</p></li>
<li><p class=""><span class="italic">Moderate NPDR:</span> The findings are more severe than mild NPDR. Cotton-wool spots venous beading and IRMA are present but mild.</p></li>
<li><p class=""><span class="italic">Severe NPDR:</span> At least one of the following should be present: (a) Severe hemorrhages and microaneurysms in all four quadrants, (b) Severe venous beading in two quadrants, and (c) IRMA-more severe in one quadrant.</p></li>
<li><p class=""><span class="italic">Very severe NPDR:</span> Two or more of above criteria, but without any proliferative changes.</p></li>
</ul></p>
<p class=""><span class="italic">Diabetic maculopathy:</span> Clinically significant macular edema (CSME) <bold>(<a href="#ch18fig37" class="ulink-inter">Fig. 18.37</a>)</bold> is described as:</p>
<p class=""><ul style="list-style-type: bullet">
<li><p class="">Retinal thickening at or within 500 µm at the center of macula.</p></li>
<li><p class="">Hard exudates at or within 500 µm of the center of macula.</p></li>
<li><p class="">An area of retinal thickening greater than 1 dd area in size, at least a part of which is within 1 dd of the center of the macula.</p></li>
</ul></p>
<p class=""><span class="italic">PDR:</span> Neovascularization is the hallmark of PDR.</p>
<p class=""><span class="italic">Advanced PDR:</span> Same as advanced diabetic eye diseases.</p>
</div>
</div>
<div class="section" id="ch18lev2sec40"><h2 class="title">Proliferative Diabetic Retinopathy</h2>
<p class="noindent">It affects about 5% of the diabetic population, and more with insulin-dependent diabetes mellitus (IDDM).<a name="page358"></a><span class="pageBreak"></span><span class="pageNumbers"><span class="bottomPage">358</span></span></p>
<div class="figure" id="ch18fig37" data-label="Fig. 18.37"><div class="title"><span class="item-label">Fig. 18.37</span> Non-proliferative diabetic retinopathy—clinically significant macular edema (CSME).</div><img alt="Fig. 18.37" src="/MediumImage/358-1.jpg"><div class="additional-markup"></div></div>
<div class="section" id="ch18lev3sec29"><h3 class="title">Clinical Features</h3>
<ul style="list-style-type: bullet">
<li><p class=""><span class="italic">Neovascularization</span> is the hallmark of PDR.</p>
<p class="">It may be on the optic nerve head [<bold>NVD</bold>—<span class="italic">new vessels at the disc (<a href="#ch18fig38" class="ulink-inter">Fig. 18.38</a>)</span>], or along the course of major blood vessels <bold>[(NVE</bold>—<span class="italic">new vessels elsewhere (<a href="#ch18fig36" class="ulink-inter">Fig. 18.36</a>)]</span>. Over one-fourth of the retina has to be ischemic (non-perfused), before NVD appear. The new vessels start as endothelial proliferations, arising from the veins. The vessels are enveloped by mesenchymal fibroblasts forming a fibrovascular epiretinal membrane. NVD are more dangerous than NVE, as they have a greater propensity to bleed.</p>
<p class="">FFA shows hyperfluorescent areas with leakage from the new vessels.</p></li>
<li><p class=""><span class="italic">Posterior vitreous detachment</span> is extremely important in the progression of PDR.</p></li>
<li><p class=""><span class="italic">Hemorrhage</span> may occur in the form of intraretinal, preretinal and vitreous hemorrhage.</p>
<p class="">A preretinal or <bold>subhyaloid hemorrhage (<a href="#ch18fig39" class="ulink-inter">Fig. 18.39</a>)</bold> has a crescentic or boat-shaped configuration, which demarcates the level of posterior vitreous detachment.</p></li>
</ul>
</div>
</div>
<div class="section" id="ch18lev2sec41"><h2 class="title">Advanced Diabetic Eye Diseases</h2>
<p class="noindent">The end results of uncontrolled PDR are:</p>
<ul style="list-style-type: bullet">
<li><p class="">Recurrent vitreous hemorrhages.</p></li>
<li><p class="">Tractional retinal detachment.</p></li>
<li><p class=""><span class="italic">Burn-tout proliferative diabetic retinopathy:</span> In persistent PDR, after a variable period of time, the fibrous component of the fibrovascular proliferation becomes more evident, and the vascular component decreases. Then, the blood vessels become nonperfused, and no further proliferation occurs. This is called <span class="italic">burnt-out PDR</span>.</p></li>
<li><p class=""><span class="italic">Neovascular glaucoma:</span> Rubeosis iridis is a fairly common finding in eyes with PDR, and may lead to the development of neovascular glaucoma. It is more in patients following unsuccessful pars plana vitrectomy.</p></li>
</ul>
<div class="figure" id="ch18fig38" data-label="Fig. 18.38"><div class="title"><span class="item-label">Fig. 18.38</span> Neovascularization of the disc (NVD).</div><img alt="Fig. 18.38" src="/MediumImage/358-2.jpg"><div class="additional-markup"></div></div>
<div class="figure" id="ch18fig39" data-label="Fig. 18.39"><div class="title"><span class="item-label">Fig. 18.39</span> Subhyaloid hemorrhage.</div><img alt="Fig. 18.39" src="/MediumImage/358-3.jpg"><div class="additional-markup"></div></div>
<p class=""><a name="page359"></a><span class="pageBreak"></span><span class="pageNumbers"><span class="bottomPage">359</span></span></p>
</div>
<div class="section" id="ch18lev2sec42"><h2 class="title">Management of Diabetic Retinopathy</h2>
<div class="section" id="ch18lev3sec30"><h3 class="title">General</h3>
<ul style="list-style-type: bullet">
<li><p class=""><span class="italic">Metabolic control:</span> Careful control of diabetes during first 5 years of the disease may reduce the severity, or delay the onset of DR. But, it apparently has little, or no effect on the established condition.</p></li>
<li><p class=""><span class="italic">Control of hypertension:</span> Strict control of systemic hypertension is important.</p></li>
<li><p class=""><span class="italic">Anemia:</span> Should be treated promptly.</p></li>
<li><p class=""><span class="italic">Aspirin and dipyridamole:</span> It may have beneficial effect as they decrease platelet adhesiveness.</p></li>
<li><p class=""><span class="italic">Clofibrate:</span> It is used to decrease lipid concentration.</p></li>
</ul>
</div>
<div class="section" id="ch18lev3sec31"><h3 class="title">Specific Treatment</h3>
<ul style="list-style-type: bullet">
<li><p class=""><span class="italic">Non-proliferative DR:</span> No treatment is required for NPDR with normal visual acuity except, periodic annual examination.</p></li>
<li><p class=""><span class="italic">Diabetic maculopathy</span>
<ul style="list-style-type: square">
<li><p class=""><span class="italic">Focal maculopathy:</span> Focal argon-laser photocoagulation is required, around the microaneurysms or leaking vessels.</p></li>
<li><p class=""><span class="italic">Diffuse maculopathy:</span> Macular grid photocoagulation <bold>(<a href="#ch18fig40" class="ulink-inter">Fig. 18.40</a>)</bold> is required, but avoiding the fovea (the burns should not be closer than 500 µ from the foveola). The results are much less favorable than for focal maculopathy.</p></li>
<li><p class=""><span class="italic">Ischemic maculopathy:</span> Photocoagulation will not improve vision. Follow-up is essential, as about 30% will develop PDR within 2 years.</p></li>
</ul></p></li>
<li><p class=""><span class="italic">Pre-proliferative DR:</span> The patients should be watched very closely. Treatment by photocoagulation is usually unnecessary, unless FFA shows extensive areas of capillary non-perfusion. Gentle argon laser photocoagulation is done to the areas of capillary non-perfusion, or in a panretinal fashion.</p></li>
<li><p class=""><span class="italic">Proliferative DR:</span> Photocoagulation is the most important modality for the treatment of PDR. Double frequency YAG (532) laser, argon laser or diode laser is used for photocoagulation.</p></li>
<li><p class=""><span class="italic">Argon laser or double frequency YAG (532) laser photocoagulation:</span> The treatment of choice in PDR, is panretinal photocoagulation (PRP) <bold>(<a href="#ch18fig41" class="ulink-inter">Fig. 18.41</a>)</bold> with a slit-lamp delivery system.</p>
<p class="">The aim of the treatment is to convert the hypoxic area into anoxic area, and thereby, to induce involution of new vessels, and to prevent recurrent vitreous hemorrhage.</p>
<p class="">PRP is performed in two or more sessions, as, if done in one session, it causes more serious complications. The new vessels usually take 4–8 weeks’ time to regress after adequate PRP.</p>
<p class=""><div class="figure" id="ch18fig40" data-label="Fig. 18.40"><div class="title"><span class="item-label">Fig. 18.40</span> Macular grid photocoagulation in diabetic maculopathy.</div><img alt="Fig. 18.40" src="/MediumImage/359-1.jpg"><div class="additional-markup"></div></div></p>
<p class=""><div class="figure" id="ch18fig41" data-label="Fig. 18.41"><div class="title"><span class="item-label">Fig. 18.41</span> Panretinal photocoagulation.</div><img alt="Fig. 18.41" src="/MediumImage/359-2.jpg"><div class="additional-markup"></div></div></p></li>
<li><p class=""><a name="page360"></a><span class="pageBreak"></span><span class="pageNumbers"><span class="bottomPage">360</span></span><span class="italic">Advanced diabetic eye diseases</span>
<ul style="list-style-type: square">
<li><p class=""><span class="italic">Vitreous hemorrhage:</span> Pars plana vitrectomy with panretinal endolaser photocoagulation.</p></li>
</ul></p></li>
<li><p class=""><span class="italic">Tractional RD:</span> Pars plana vitrectomy is only to be undertaken when detachment has progressed to involve the macula.</p></li>
<li><p class=""><span class="italic">Neovascular glaucoma:</span> As described in <a href="/9789356963825/chapter/ch16" class="ulink-exter">Chapter 16</a>.</p></li>
</ul>
</div>
</div>
</div><div class="section" id="ch18lev1sec22"><h1 class="title">OTHER OCULAR SIGNS IN DIABETES MELLITUS</h1>
<p class="noindent"><span class="italic">Visual defects</span></p>
<ul style="list-style-type: bullet">
<li><p class="">Transient variations in refraction:
<ul style="list-style-type: square">
<li><p class="">Hyperglycemia → increased refractive index of the lens → myopic shift</p></li>
<li><p class="">Hypoglycemia → decreased refractive power of the lens → hypermetropic shift</p></li>
</ul></p></li>
<li><p class="">Photopsia and diplopia in cerebral hypoglycemia</p></li>
<li><p class="">Decreased accommodation</p></li>
<li><p class="">Diplopia in ophthalmoplegia caused by neuropathy</p></li>
<li><p class="">Decreased vision in cataract, maculopathy and vitreous hemorrhage</p></li>
<li><p class="">Complete blindness from tractional RD, massive vitreous proliferation and neovascular glaucoma.</p></li>
</ul>
<p class="noindent"><span class="italic">Ocular movements</span></p>
<ul style="list-style-type: bullet">
<li><p class="">Neuropathy with muscle paralysis (pupillary sparing in third nerve palsy)</p></li>
<li><p class="">Painful ophthalmoplegia.</p></li>
</ul>
<p class="noindent"><span class="italic">Lids</span></p>
<ul style="list-style-type: bullet">
<li><p class="">Increased incidence of stye or internal hordeolum</p></li>
<li><p class="">Xanthelasma (due to associated hyperlipidemia).</p></li>
</ul>
<p class="noindent"><span class="italic">Conjunctiva</span></p>
<ul style="list-style-type: bullet">
<li><p class="">Tortuous and constricted blood vessels</p></li>
<li><p class="">Sludging of the blood.</p></li>
</ul>
<p class="noindent"><span class="italic">Cornea</span></p>
<ul style="list-style-type: bullet">
<li><p class="">Delayed epithelial healing due to abnormality in epithelial basement membrane</p></li>
<li><p class="">Punctate keratopathy</p></li>
<li><p class="">Increased incidence of infective keratitis with delayed healing</p></li>
<li><p class="">Wrinkling of the Descemet's membrane</p></li>
<li><p class="">Decreased corneal sensation (due to trigeminal neuropathy)</p></li>
<li><p class="">Increased prevalence of dry eye.</p></li>
</ul>
<p class="noindent"><span class="italic">Iris</span></p>
<ul style="list-style-type: bullet">
<li><p class="">Hydrops of the pigment epithelium (due to transient glycogen storage) release of pigment into the anterior chamber during surgery, or simply, even after dilatation of the pupil.</p></li>
<li><p class=""><span class="italic">Rubeosis iridis</span>.</p></li>
</ul>
<p class="noindent"><span class="italic">Lens</span></p>
<ul style="list-style-type: bullet">
<li><p class="">Variation in refractive power [during hyperglycemia increased glucose content (sorbitol) of the lens cortex → imbibition of water → increased thickness of the lens → increased refractive power].</p></li>
<li><p class="">Typical snowflake (sugar) cataract in IDDM</p></li>
<li><p class="">Posterior cortical cataract</p></li>
<li><p class="">Early onset of senile cataract.</p></li>
</ul>
<p class="noindent"><span class="italic">Vitreous</span></p>
<ul style="list-style-type: bullet">
<li><p class="">Vitreous hemorrhage</p></li>
<li><p class="">Fibrovascular proliferation in the vitreous.</p></li>
</ul>
<p class="noindent"><span class="italic">Retina</span></p>
<ul style="list-style-type: bullet">
<li><p class="">Diabetic retinopathy (as already discussed)</p></li>
<li><p class="">Lipemia retinalis (due to associated triglyceridemia, in ketoacidosis)</p></li>
<li><p class="">Central retinal venous occlusion</p></li>
<li><p class="">Diabetic retinopathy with superimposed changes of severe vascular hypertension—as seen in IDDM with renal failure.</p></li>
</ul>
<p class="noindent"><span class="italic">Intraocular pressure</span></p>
<ul style="list-style-type: bullet">
<li><p class="">Decreased in diabetic ketoacidosis (due to increased plasma bicarbonate level)</p></li>
<li><p class="">Increased in neovascular glaucoma</p></li>
<li><p class="">Increased incidence of POAG.</p></li>
</ul>
</div><div class="section" id="ch18lev1sec23"><h1 class="title">RETINOBLASTOMA</h1>
<p class="noindent">Discussed in <a href="/9789356963825/chapter/ch20" class="ulink-exter">Chapter 20</a>.</p>
</div></div></div>